Archive for November, 2017

$UEPS Bitstamp Partners with Net1’s Masterpayment for Cryptocurrency Purchases

JOHANNESBURG, SOUTH AFRICA–(November 22, 2017) – Net 1 UEPS Technologies, Inc. (“Net1” or the “Company” (NASDAQ: UEPS) (JSE: NT1) today announced that its wholly owned subsidiary, Masterpayment, an independent Payment Processor specializing in the requirements of the new cryptocurrency markets, has been appointed as a new partner for credit card processing and acquiring for cryptocurrency purchases for Bitstamp, a leading global digital currency exchange and the largest Bitcoin exchange in the EU in terms of volume. This partnership will allow Bitstamp customers to enjoy faster and more convenient transactions, while maintaining the same high-caliber security.

Masterpayment merges the core capabilities of an acquirer with those of a payment service provider and adds the regulatory framework of a renowned bank, which provides added value as for an example, the payout in 14 settlement currencies, as well as corporate accounts via the in-house acquiring bank. Bitstamp customers can still spend USD or EUR using Visa, Mastercard credit or debit cards to purchase bitcoin, litecoin, ethereum and ripple. The daily buying limit of 5000 USD/EUR and monthly buying limit of 20,000 USD/EUR remain the same, with transaction fees decreasing to 5 percent.

“Here at Bitstamp, we’ve always sought to make access to digital currencies as safe, simple and secure as possible,” said Miha Grčar, Head of Business Development at Bitstamp. “That’s why we are excited about our partnership with Masterpayment, which is ideally positioned to help us follow through on these goals.”

Bitstamp sets aggressive goals for customer satisfaction in the rapidly evolving cryptocurrency environment. In just the past four months, Bitstamp announced the launch of ether on its trading platform, a partnership with Swissquote to offer bitcoin trading on the online bank’s platform, and making newly generated bitcoin addresses at Bitstamp Segwit compatible. Partnerships with providers like Masterpayment allow Bitstamp to continue to meet the demands of a growing customer base as the industry becomes more mainstream.

“We are proud to be working with Bitstamp to lay the foundation for a long-term partnership in the field of cryptocurrencies. The demand of users for flexible payment methods is increasing and we look forward to being able to provide that,” said Christian Mangold, Managing Director at Masterpayment.

Bitstamp customers will experience smoother and faster purchases as well as enhanced security. Standardized security procedures such as 3D Secure, as well as special fraud-prevention mechanisms between the payment gateway and Bitstamp based on bilaterally accepted parameters, ensure a permanent fine-tuning of the risk system and monitoring of transactions.

About Net1 (www.net1.com)

Net1 is a leading provider of alternative payment systems that leverage its Universal Electronic Payment System (“UEPS”) or utilize its proprietary mobile technologies. The Company operates market-leading payment processors in South Africa and the Republic of Korea. Through Transact24, Net1 offers debit, credit and prepaid processing and issuing services for Visa, MasterCard and ChinaUnionPay in China and other territories across Asia-Pacific, Europe and Africa, and the United States. Through Masterpayment, Net1 provides payment processing and enables working capital financing in Europe.

UEPS permits the Company to facilitate biometrically secure, real-time electronic transaction processing to unbanked and under-banked populations of developing economies around the world in an online or offline environment. Net1’s UEPS/EMV solution is interoperable with global EMV standards that seamlessly enable access to all the UEPS functionality in a traditional EMV environment. In addition to payments, UEPS can be used for banking, healthcare management, payroll, remittances, voting and identification.

Net1’s mobile technologies include its proprietary mobile payments solution — MVC, which offers secure mobile-based payments, as well as mobile banking and prepaid value-added services in developed and emerging countries.

Net1 has a primary listing on the NASDAQ and a secondary listing on the Johannesburg Stock Exchange.

About Bitstamp

Founded in 2011, Luxembourg-based Bitstamp is a leading global digital currency exchange and the largest Bitcoin exchange in the EU in terms of volume. Bitstamp’s objective is to continue to be an easy-to-use and reliable one-stop shop for cryptocurrency trading in a fully compliant and regulated environment. Currently offering trading between BTC, XRP, LTC, ETH, USD and EUR, Bitstamp was the first bitcoin exchange to implement hot/cold storage and the high-security multi-sig wallet. As the longest standing digital currency exchange in Europe, Bitstamp is uniquely positioned to bridge the gap between the traditional financial and digital currency worlds. Safe, simple and secure to use, Bitstamp provides its individual and institutional clients with an intuitive and engaging environment for trading and custodial services. www.bitstamp.net

About Masterpayment (www.masterpayment.com)

Masterpayment combines the core capabilities of an acquirer with those of a payment service provider and adds the regulatory framework of a renowned bank into the service portfolio at leading edge prices. As first mover, Masterpayment, has specialized in the white label acquiring and payment processing requirements for all kind of MCC´s like Cryptocurrencies, Wallets, Digital Entertainment, Gambling, etc. Masterpayment supports the merchant and provides added value, as an example, the payout in 14 settlement currencies, as well as corporate accounts, via the in-house acquiring bank. Masterpayment was founded in 2010 and has subsidiaries in Germany, the UK, Liechtenstein and Malta.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, included in this press release regarding strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. Factors that might cause such differences include, but are not limited to failure by the Company to realize the anticipated benefits from these arrangements; and other factors, many of which are beyond the Company’s control; and other important factors included in the Company’s reports filed with the Securities and Exchange Commission, particularly in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017, as such Risk Factors may be updated from time to time in subsequent reports. The Company does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Dhruv Chopra
Head of Investor Relations
Phone: +1-917-767-6722
Email: dchopra@net1.com

Media Relations Contact

Bridget von Holdt
Business Director — Burson-Marstellar South Africa
Phone: +27-82-610-0650
Email: bridget.vonholdt@bm-africa.com

Wednesday, November 22nd, 2017 Uncategorized Comments Off on $UEPS Bitstamp Partners with Net1’s Masterpayment for Cryptocurrency Purchases

$NXTD Responds to Shareholder Questions

MELBOURNE, Florida, November 22, 2017 —

NXT-ID, Inc. (NASDAQ: NXTD) (“NXT-ID” or the “Company”), a security technology company issued the following response to recent shareholder inquiries concerning the recent downward volatility of its stock.

Gino Pereira, Chief Executive Officer of NXT-ID commented, “We believe the strong downward pressure on the stock in the recent days is not reflective of the underlying value of our company. The prospects of the Company are unchanged from the information in the recently filed 10Q and on the related earnings call.

“On year-to-year basis, we continue to out-perform in terms of revenue, gross profit, and operating income, particularly through LogicMark, which continues to perform at record levels. As was announced recently, the activation of Garmin Pay represents the successful commercialization of FitPay’s payment platform, which means that subsidiary is on track to contribute to revenue early in 2018.”

Added Pereira, “Equally as important as a result of the recent financing, we’ve begun taking steps to opportunistically reduce our debt. While that resulted in some dilution, it better positions the Company to refinance our existing debt facility, which we are actively pursuing.  We have a number of significant business development opportunities that we are pursuing in Q4 2017 and remain confident that the Company is poised for continued significant growth in 2018.”

About NXT-ID, Inc.

NXT-ID, Inc. (NASDAQ: NXTD) provides a comprehensive platform of technology products and services that enable the Internet of Things (IoT). With extensive experience in access control, biometric and behavior-metric identity verification, security and privacy, encryption and data protection, payments, miniaturization and sensor technologies, NXT-ID develops and markets groundbreaking solutions for payment and IoT applications. Its industry-leading technology products and solutions include MobileBio®, a suite of biometric solutions that secure consumers’ mobile platforms, the Wocket™, a next-generation smart wallet and the Flye, a digital credit card developed in collaboration with WorldVentures.

NXT-ID includes three mobile and IoT-related subsidiaries: LogicMark, LLC, a manufacturer and distributor of non-monitored and monitored personal emergency response systems (“PERS”) sold through dealers/distributors and the United States Department of Veterans Affairs; Fit Pay, Inc., a proprietary technology platform that delivers end-to-end solutions to device manufacturers for contactless payment capabilities, credential management, authentication and other secure services within the IoT ecosystem, and 3D-ID LLC, which is engaged in biometric identification and authentication. Learn more about NXT-ID at www.nxt-id.com.

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

NXT-ID Inc. Contact:
Corporate info: info@nxt-id.com

Media:
Chris Orlando
chris.orlando@nxt-id.com

D. Van Zant
+1-800-665-0411
press@nxt-id.com

Wednesday, November 22nd, 2017 Uncategorized Comments Off on $NXTD Responds to Shareholder Questions

$CLNT Enters into Conditional Share Swap Agreement with Marvel Finance

HONG KONG, Nov. 22, 2017 Cleantech Solutions International, Inc. (“Cleantech Solutions” or “the Company”) (“CLNT”) (Nasdaq: CLNT) today announced that its wholly-owned subsidiary, Vantage Ultimate Limited (“Vantage”), has entered into a conditional share swap agreement with Marvel Finance Limited (“Marvel”), to acquire Marvel’s 51% interest in the issued share capital of Integrated Media Technology Limited (“IMT”) (Nasdaq: IMTE). The terms of the agreement provide that Marvel shall transfer 51% of the issued share capital of IMT (which is valued at US$13,482,410, based on 1,348,241 ordinary voting shares at a price of US$10.00 per IMT share). In exchange, the Company shall issue a certain number of its shares of common stock, representing 19.5% of the issued and outstanding shares of CLNT, and a 5-year interest-free promissory note with a principal amount of US$11,482,410 to Marvel. The agreement is subject to various conditions, including entry into a definitive agreement satisfactory to both parties and legal and financial due diligence.

“We are excited about our collaboration with Dr. Herbert Ying Chiu Lee, Founder and CEO of IMT, as we explore the development of advanced technologies,” said Parkson Yip, COO of Cleantech Solutions. “Dr. Lee has extensive experience in technology research and development management, particularly in knowledge management systems and 3D autostereoscopic displays. We believe Dr. Lee will make valuable contributions that will enable CLNT to enhance our technological capabilities and advance our products and services in a more effective and customer-driven manner.”

There can be no assurances that the parties may enter into any agreement to do a transaction, and even if an agreement is entered into, there can be no assurances that such transaction will be consummated.

About Cleantech Solutions International

Cleantech Solutions International (“CLNT”), through its affiliated companies, designs, manufactures and distributes a line of proprietary high and low temperature dyeing and finishing machinery to the textile industry. The Company’s latest business initiatives are focused on targeting the technology and global sharing economy markets, by developing online platforms and rental business partnerships that will drive the global development of sharing through economical rental business models.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company and its subsidiary and affiliated companies and certain potential transactions that they may enter into. These forward looking statements are often identified by the use of forward looking terminology such as “believes,” “expects” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website, including factors described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K for the year ended December 31, 2016 and in our Form 10-Q for the quarter ended September 30, 2017. All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.

Company Contacts:
Cleantech Solutions International, Inc.
Parkson Yip, Chief Operating Officer
E-mail: parkson.yip@cleantechsolutionsinternational.com
+852-31060372
Web: www.cleantechsolutionsinternational.com

Elaine Ketchmere, CFA
Compass Investor Relations
310-528-3031
eketchmere@compass-ir.com

Wednesday, November 22nd, 2017 Uncategorized Comments Off on $CLNT Enters into Conditional Share Swap Agreement with Marvel Finance

$IGC Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 15, 2017

Seeks to Obtain a Quorum of Voting Stockholders Owning Shares as of October 5, 2017

BETHESDA, Md., Nov. 22, 2017 – India Globalization Capital, Inc. (NYSE American:IGC), adjourned again the voting for Proposals Three and Four from its Notice of Annual Meeting of Shareholders, dated October 5, 2017.  Proposal Three seeks approval of the grant of 1,900,000 shares of common stock to be granted from time to time to the Company’s current and new employees, advisors, directors, and consultants by the board of directors, pursuant to certain metrics including performance, vesting and incentive as set by the board of directors and or the CEO; and Proposal Four seeks approval of the issuance of up to 2,000,000 shares of the Company’s common stock to Bricoleur Partners, L.P.

The voting on these two proposals was adjourned to December 15, 2017 at 12:00 am Eastern Standard Time to allow the Company’s stockholders additional time to vote. Stockholders who have already voted do not need to recast their votes. Proxies previously submitted in respect of the meeting will be voted at the adjourned meeting unless properly revoked. During the period of the adjournment, the Company will continue to solicit proxies from its stockholders only with respect to the Proposals Three and Four of the Annual Meeting. No changes have been made in the proposals to be voted on by stockholders at the annual meeting. The Company’s proxy statement and any other materials filed by the Company with the SEC remain unchanged and can be obtained free of charge at the SEC’s website at www.sec.gov.

The Company encourages all stockholders who have not yet voted to do so before December 14, 2017 at 11:59 p.m., Eastern Standard Time. The stockholders may vote by internet at www.proxyvote.com, or by telephone at 800-454-8683, or by returning a properly executed proxy card to InvestorCom.

“We have two businesses: continuing legacy operations and canna-pharmaceuticals. We have filed six cannabis-based patents addressing various ailments and expect to make our most advanced and promising formulation, Hyalolex for Alzheimer’s, available to patients in select U.S. states in the first two months of 2018. Roughly 5.3 million individuals in the U.S. and 44 million worldwide suffer from this debilitating disease. Our formulation, Hyalolex, has been shown to address the primary indicators of Alzheimer’s, plaques and tangles, as well as alleviate several end points of the disease like anxiety and sleep disorder.  Importantly, this is achieved without the patient getting high, or suffering long-term damage to neurons,” states Ram Mukunda, IGC CEO.

About IGC:
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA.
For more information please visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements:
Please see forward-looking statements and risk factors as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact at IGC:
Claudia Grimaldi
301-983-0998

Contact at InvestorCom, Inc.
Michelle Frosch
877-972-0090

Wednesday, November 22nd, 2017 Uncategorized Comments Off on $IGC Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 15, 2017

$RIOT Appoints Investment Executive Frank M. Bishop to Advisory Board

CASTLE ROCK, Colo., Nov. 21, 2017 — Riot Blockchain, Inc. (Nasdaq: RIOT) (the “Company”) today announced that it has appointed Frank M. Bishop to the Riot Blockchain Advisory Board.  Mr. Bishop served as a member of the senior management team that built INVESCO into one of the largest publicly traded global investment management companies.  During Mr. Bishop’s tenure at INVESCO, he served as the President and Chief Executive Officer of both INVESCO Capital Management and INVESCO, Inc., the North American operating subsidiary of AMVESCAP, PLC, which later became INVESCO, Ltd. (NYSE: IVZ).

“Frank brings a great depth of finance and investment experience from his tenure as President and CEO of INVESCO,” commented John O’Rourke, Chairman and Chief Executive Officer of Riot Blockchain. “We are thrilled to have Frank join our Advisory Board, and look forward to his insight as we aim to become a leader in blockchain technologies.”

Mr. Bishop is presently the General Partner of AL III Management Co., an investment partnership with a focus on early stage equity investments. Additionally, Mr. Bishop serves as Chairman of the Board of MDL AutoMation, a systems and software provider to the retail automotive industry.  In his prior role at INVESCO, Mr. Bishop served as a director to multiple INVESCO management and advisory companies, including INVESCO Realty Advisors, INVESCO Management & Research, and PRIMCO Capital Management.

The blockchain is a decentralized and encrypted ledger that offers a secure, efficient, verifiable and permanent way of storing records and other information without the need for intermediaries. These protocols are the backbone of numerous digital cryptocurrencies, including Bitcoin, Ethereum and Litecoin. Blockchain protocols have a wide range of use, including processing transactions, accounting, verification and proof of ownership across a far-reaching spectrum of applications.

About Riot Blockchain

Riot Blockchain, Inc., (formerly Bioptix, Inc.) leverages its expertise and network to build and support blockchain technologies. It is establishing an Advisory Board with technical experience intending to become a leading authority and supporter of blockchain, while providing investment exposure to the rapidly growing Bitcoin and blockchain ecosystems. For more information, visit http://www.RiotBlockchain.com/.

The company continues to maintain its Bioptix business segment, including its royalty license stemming from an Exclusive License Agreement with Ceva Santé Animale S.A., providing an exclusive worldwide royalty-bearing license, until December 31, 2028, to develop, seek regulatory approval for and offer to sell, market, distribute, import and export luteinizing hormone and/or follicle-stimulating hormone products for cattle, equine and swine for the assistance and facilitation of reproduction.

Safe Harbor

The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the sections entitled “Risk Factors”, copies of which may be obtained from the SEC’s website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Media Contacts
Karen Chase or Travis Kruse
Russo Partners, LLC
(646) 942-5627
(212) 845-4272
karen.chase@russopartnersllc.com
travis.kruse@russopartnersllc.com

Investor Contact
IR@RiotBlockchain.com

Tuesday, November 21st, 2017 Uncategorized Comments Off on $RIOT Appoints Investment Executive Frank M. Bishop to Advisory Board

$RESN to Present at 10th Annual LD Micro Main Event

GOLETA, CA–(November 21, 2017) – Resonant Inc. (NASDAQ: RESN), a designer of filters for radio frequency, or RF, front-ends that specializes in delivering designs for difficult bands and complex requirements, today announced that management is scheduled to present at the LD Micro Main Event Investor Conference in Bel Air, California. The conference is being held December 5-7, 2017 at the Luxe Sunset Boulevard Hotel in Bel Air, California.

Resonant management will host one-on-one meetings throughout the day on Tuesday, December 5, 2017, and is scheduled to present as follows:

LD Micro Main Event

Date: Tuesday, December 5, 2017

Presentation Time: 5:30 p.m. Pacific standard time

Location: Luxe Sunset Boulevard Hotel, Track 2 (11461 Sunset Blvd, Bel Air)

The presentation will be webcast and available following the live presentation. The webcast can be viewed at http://wsw.com/webcast/ldmicro13/resn/.

Conference participation is by invitation only and registration is mandatory. For more information or to schedule a one-on-one meeting, please contact an LD Micro representative.

About Resonant Inc.

Resonant is creating software tools and IP & licensable blocks that enable the development of innovative filter designs for the RF front-end, or RFFE, for the mobile device industry. The RFFE is the circuitry in a mobile device responsible for the radio frequency signal processing and is located between the device’s antenna and its digital baseband. Filters are a critical component of the RFFE that selects the desired radio frequency signals and rejects unwanted signals and noise. For more information, please visit www.resonant.com.

About Resonant’s ISN® Technology

Resonant can create designs for difficult bands and complex requirements that we believe have the potential to be manufactured for half the cost and developed in half the time of traditional approaches. The Company’s large suite of proprietary mathematical methods, software design tools and network synthesis techniques enable it to explore a much bigger set of possible solutions and quickly derive the better ones. These improved filters still use existing manufacturing methods (i.e. SAW) and can perform as well as those using higher cost methods (i.e. BAW). While most of the industry designs surface acoustic wave filters using a coupling-of-modes model, Resonant uses circuit models and physical models. Circuit models are computationally much faster, and physical models are highly accurate models based entirely on fundamental material properties and dimensions. Resonant’s method delivers excellent predictability, enabling achievement of the desired product performance in roughly half as many turns through the fab. In addition, because Resonant’s models are fundamental, integration with its foundry and fab customers is eased because its models speak the “fab language” of basic material properties and dimensions.

Investor Relations Contact:
Greg Falesnik
MZ North America
1-949-385-6449
Greg.Falesnik@mzgroup.us

Tuesday, November 21st, 2017 Uncategorized Comments Off on $RESN to Present at 10th Annual LD Micro Main Event

$ACIU to Host Key Opinion Leader Meeting on Tau IN Alzheimer’s

Lausanne, Switzerland, November 21, 2017 – AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will host a Key Opinion Leader (KOL) luncheon meeting on the importance of Tau as a target in Alzheimer’s disease and other neurodegenerative diseases on December 1, 2017 from 12.00pm – 1.45pm ET at the St. Regis Hotel, 2 E. 55th Street in New York, NY.

The meeting will feature presentations by KOLs Khalid Iqbal, PhD (New York State Institute for Basic Research in Developmental Disabilities) and Michael Rafii, MD, PhD (UC San Diego). They  will discuss the mechanism and importance of Tau in the pathology and treatment of Alzheimer’s and other neurodegenerative diseases, the role of diagnostics in Alzheimer’s and a review of research on Tau and Amyloid in people with Down syndrome.

AC Immune’s management team will provide an overview of the Company’s robust and diverse pipeline of nine therapeutic and three diagnostic product candidates. The Company has a clear strategy to invest and build value in each of the three pillars of its business — Alzheimer’s disease, other significant neurodegenerative diseases and neuro-orphan indications, and diagnostics.

A Q&A session with the featured KOLs and the management will follow the presentations.

This event is intended for institutional investors, sell-side analysts, and pharmaceutical business development professionals only. Please RSVP in advance if you plan to attend, as space is limited.

A live webcast and replay of the event will be available on the Investor Page of AC Immune’s website.

KOL Biographies

Khalid Iqbal, PhD
Dr. Khalid Iqbal is Professor and Chairman, Department of Neurochemistry at the New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York. He received his PhD in Biochemistry in 1969 from the University of Edinburgh, Edinburgh, U.K. Dr. Iqbal was the first to bulk-isolate neurofibrillary tangles and decipher their protein composition from autopsied brains of cases with Alzheimer’s disease in 1974. These pioneering studies led him to the discoveries of Tau protein as the major protein subunit of the tangles and its abnormal hyperphosphorylation in Alzheimer’s disease in 1986. Dr. Iqbal has received numerous awards, including the Potamkin Prize for Alzheimer Disease Research from the American Academy of Neurology, the Zenith Award from the Alzheimer’s Association, U.S.A and Honorary Doctor of Science degree from the City University of New York College of Staten Island. In 2007, Alzheimer’s Association, USA, established a Khalid Iqbal Life Time Achievement Award for Alzheimer’s Disease Research, which is given out annually at the International Conference on Alzheimer’s Disease (AAIC) to a senior established Alzheimer disease researcher. Dr. Iqbal has authored over 400 scientific papers in prestigious American and international scientific journals and edited seven books on research advances in Alzheimer’s disease and related neurodegenerative disorders. He currently serves on editorial boards of several journals and scientific advisory committees of biotechnology companies.

Michael Rafii, MD, PhD
Dr. Michael Rafii, MD, PhD, is a board-certified neurologist and Associate Professor of Neuroscience and Founding Director of the Adult Down Syndrome Clinic at UC San Diego. Dr. Rafii leads multiple research programs studying the link between Alzheimer’s disease and Down syndrome. He completed a fellowship in dementia and cognitive disorders at UC San Diego. He completed his neurology residency at the Johns Hopkins Hospital, where he was chief resident. He received his medical and doctorate degrees from Brown University School of Medicine and conducted neurogenetics research at Harvard Medical School. Dr. Rafii serves on the National Task Group on Intellectual Disabilities and Dementia Practices of the American Academy of Developmental Medicine and is co-editor of the textbook Common Pathogenic Mechanisms between Down Syndrome and Alzheimer’s Disease: Steps toward Therapy. Dr. Rafii received the Star Award from the Down Syndrome Association of San Diego for his efforts to improve the lives of people with this condition. He is also Clinical Director of the Alzheimer’s Therapeutic Research Institute (ATRI) at the Keck School of Medicine of USC.

About AC Immune
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer’s disease (AD). The Company’s pipeline features nine therapeutic and three diagnostic product candidates. The most advanced of these is crenezumab, an anti-Abeta antibody in Phase 3 clinical studies for AD that is being conducted by the collaboration partner Genentech. Other collaborations include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences, Piramal Imaging and Essex Bio-Technology.

Forward Looking Statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information-Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission.  Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

For further information, please contact:

In Europe
Eva Schier
AC Immune Corporate Communications
Phone: +41 21 345 91 34
E-mail: eva.schier@acimmune.com
In the US
Lisa Sher
AC Immune Investor Relations
Phone: +1 970 987 26 54
E-mail: lisa.sher@acimmune.com
Nick Miles /Toomas Kull
Cabinet Privé de Conseils s.a.
Phone: +41 22 552 46 46
E-mail: miles@cpc-pr.com
kull@cpc-pr.com
Ted Agne
The Communications Strategy Group Inc.
Phone: +1 781 631 3117
E-mail: edagne@comstratgroup.com
Tuesday, November 21st, 2017 Uncategorized Comments Off on $ACIU to Host Key Opinion Leader Meeting on Tau IN Alzheimer’s

$DMPI Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM

40% of recurrent GBM patients treated to date achieved stable disease as measured by magnetic resonance imaging (MRI)

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 21, 2017  — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, today provided an overview of three scientific posters presented at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) held on November 16-19, 2017 in San Francisco, CA.

DelMar reported that 96% of patients enrolled were alive at the time of the analysis and 40% of patients enrolled were reported to have achieved stable disease as assessed by MRI following treatment with VAL-083 as a single agent.  “While it is too early to interpret overall survival results from this study, the substantial disease control observed to date in the treatment recurrent GBM, ‎an aggressive tumor that can double in size within 6-8 weeks, is an important and positive observation at this stage,” said Mr. Saiid Zarrabian, DelMar’s Interim Chief Executive Officer.

“The promising early observations from our ongoing Phase 2 clinical trial of VAL-083 as a potential new treatment option for MGMT-unmethylated GBM are also supported by extensive preclinical research into VAL-083’s unique mechanism of action,” added Mr. Zarrabian.  “Based on these recent data, we believe VAL-083 represents a potential solution for some of the most important unmet medical needs in the treatment of GBM and other central nervous system tumors.”

DelMar provided an update on the company’s ongoing Phase 2 clinical studies in a poster entitled “Clinical Trials with dianhydrogalactitol (VAL-083) in MGMT-unmethylated Glioblastoma,” which is being conducted in collaboration with The University of Texas MD Anderson Cancer Center. This trial is designed to enroll up to 48 patients to determine if VAL-083 treatment improves overall survival compared to historical reference control.

  • DelMar reported that 27 subjects have been screened and 15 have been enrolled since the opening of recruitment in February 2017. To date, the trial has enrolled at a rate ahead of initial projections.
  • All patients enrolled in the study have recurrent MGMT-unmethylated GBM with radiographic evidence of progression and were not surgically resected at the time of enrollment.
  • DelMar reported that 96% of patients enrolled were alive at the time of the analysis and 40% of patients enrolled were reported to have achieved stable disease following treatment with VAL-083 as a single agent, as assessed by MRI.
  • Enrollment is ongoing and median survival has not yet been reached in the trial.
  • In general, VAL-083 treatment was well tolerated by patients with observed side effects (myelosuppression) similar to prior clinical experience.

The Company also provided an overview of the design a separate Phase 2 clinical trial of VAL-083 for newly diagnosed MGMT-unmethylated GBM patients on this poster. In this trial, which was recently initiated at Sun Yat-Sen University Cancer Center, patients will be treated with VAL-083 plus radiotherapy as an alternative to standard-of-care temozolomide plus radiation in the front-line setting. The trial is designed to enroll up to 30 patients with MGMT-unmethylated GBM to determine if VAL-083 treatment improves progression free survival (PFS) compared to a historical reference control. This trial is being supported though DelMar’s collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd.

In addition, DelMar also presented two additional pre-clinical posters during the conference:

  • The Distinct Cytotoxic Mechanism of Dianhydrogalactitol (VAL-083) Overcomes Chemoresistance and Provides New Opportunities for Combination Therapy in the Treatment of Glioblastoma.

VAL-083 induces potent anti-cancer activity against treatment-resistant cells from glioblastoma, lung, prostate and ovarian tumors through a distinct mechanism of action.  Cancer cells treated with VAL-083 exhibit persistent DNA double-strand breaks and activation of the homologous DNA repair (HR) system. Activation of the HR system is an indicator of VAL-083’s unique anti-tumor activity.

When combined with topoisomerase or PARP inhibitors, the treatment effect of VAL-083 is increased in a synergistic or super-additive manner. Taken together, these data support the broad potential of VAL-083 as a new treatment against a wide range of cancers both as a single agent and in combination with other established cancer therapies.

  • Dianhydrogalactitol (VAL-083) Overcomes Chemoresistance in Pediatric Malignant Brain Tumors and Displays Synergy with Topoisomerase Inhibitors

Pediatric high-grade glioma (HGG) and medulloblastoma are aggressive childhood brain tumors with a high incidence of recurrence and very few patients achieve long-term survival.  VAL-083 demostrates potent activity as a single agent against both chemo-resistant pediatric HGG and medulloblastoma independent of p53 status. DelMar also reported that VAL-083 potentiates radiotherapy and exhibits synergy when used in combination with topoisomerase inhibitors, two regimens commonly used in the treatment of childhood brain tumors.

“We continue to be highly enthusiastic about the potential of VAL-083 as a novel treatment for cancer patients who have limited or no treatment options,” added Mr. Zarrabian. “The excellent work performed by our world class academic research collaborators and our in-house team presented at the SNO meeting showcases VAL-083’s potential both as a single agent and as a component of combination therapeutic regimens.”

DelMar’s poster presentations can be viewed in their entirety on DelMar’s website at http://www.delmarpharma.com/scientific-publications.html

About VAL-083

VAL-083 (dianhydrogalactitol) is a “first-in-class”, DNA-targeting agent that introduces interstrand DNA cross-links at the N7-position of guanine leading to DNA double-strand breaks and cancer cell death. VAL-083 has demonstrated clinical activity against a range of cancers including GBM and ovarian cancer in historical clinical trials sponsored by the U.S. National Cancer Institute (NCI).  DelMar has demonstrated that VAL-083’s anti-tumor activity is unaffected by common mechanisms of chemoresistance in vitro. Further details regarding these studies can be found at http://www.delmarpharma.com/scientific-publications.html.

VAL-083 has been granted an orphan drug designation by the U.S. FDA Office of Orphan Products for the treatment of glioma, medulloblastoma and ovarian cancer, and in Europe for the treatment of malignant gliomas.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals is focused on the development and commercialization of new therapies for cancer patients who have limited or no treatment options.  By focusing on understanding tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize new therapies in indications where patients are failing, or have become resistant to modern targeted or biologic treatments.

The Company’s current pipeline is based around VAL-083, a “first-in-class,” small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in clinical trials sponsored by the NCI. Based on DelMar’s internal research programs and these prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support the development and commercialization of VAL-083 across multiple oncology indications to solve significant unmet medical needs.

VAL-083 is also being studied in two collaborator-supported, biomarker driven, Phase 2 clinical trials for MGMT-unmethylated GBM. Overcoming MGMT-mediated resistance represents a significant unmet medical need in the treatment of GBM.  DelMar also recently announced the allowance of a separate IND for VAL-083 as a potential treatment for platinum-resistant ovarian cancer.

Further information on DelMar’s clinical trials can be found on clinicaltrials.gov:  https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs

For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989.

Connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

Tuesday, November 21st, 2017 Uncategorized Comments Off on $DMPI Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM

$VRML Release of Final CMS Reimbursement Rate for OVA1

AUSTIN, Texas, Nov. 20, 2017 — ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA), and Overa (MIA2G), today announced that the Center for Medicare Services (CMS) has released the Final 2018 Clinical Lab Fee Schedule, effective January 1, 2018.

Under the new fee schedule, the price for OVA1(MIA) (code 81503) is $897.  This is a four-fold increase over the current CMS rate, and this new rate is based on the median of private payer payments submitted to CMS by companies, including ASPiRA Labs, as part of the market-based payment reform mandated through Protecting Access to Medicare Act of 2014 (PAMA). The rate is scheduled to be in effect for a three-year term from January 2018 thru December 2020.

“We are very excited that CMS has finally priced OVA1 based on market pricing which is directly related to improved patient outcomes and health economic impact.  Historically, pricing has not reflected OVA1’s benefit to improved patient outcomes, as well as the cost reductions to the healthcare system,” stated Valerie Palmieri, President and Chief Executive Officer of Vermillion, Inc. “Our health economics study published last week is another confirmation of the value of our technology.  In addition to being appropriately priced, OVA1 is now included on the Clinical Lab Fee Schedule (CLFS) for the very first time.  We expect that leveraging guidelines, payer coverage and price will be key catalysts for growth in 2018.”

“The inclusion of OVA1 on the CLFS should accelerate our contracting efforts throughout 2018,” stated Fred Ferrara, Chief Operating Officer of ASPiRA Labs.  “Several large plans use the CLFS to determine price.  We view the added CLFS visibility for our testing that was calculated using the PAMA rates as a very positive event.  We plan to expand the ASPiRA Labs sales team in strategic markets to deliver OVA1 to more women going forward, particularly given the substantial increase in covered lives expected to take effect from October 2017 through February 2018.”

The lifetime risk for all U.S. women to develop a pelvic mass is 20%. There is a 5-10% lifetime risk of requiring surgery for a suspected ovarian neoplasm. Due to the majority of the masses are benign, triaging the low and high risk masses is vital to improved patient outcomes. Today, more than 60% of U.S. ovarian cancer patients do not receive National Comprehensive Cancer Network (NCCN) guideline treatment, which includes surgical treatment by a gynecologic oncologist, and, as a result, the survival rate is reduced by 30-40%. OVA1 helps ensure that rare ovarian cancer is triaged appropriately to the gynecological oncologist and benign cysts are managed by the general practitioner, in a very cost-effective and efficient way. Vermillion’s goal is to have the right patient managed by the right specialist, with the right treatment the first time.

OVA1 is now considered a Level B Recommendation by The American College of Obstetricians and Gynecologists (ACOG). Given the November 2016 ACOG bulletin, the 2017 NCCN update and the 2013 Society of Gynecologic Oncology positive position statement, OVA1 can be the physician’s first choice in biomarker panels to best triage patients’ pelvic masses to the most appropriate care pathway. There is no other comparable technology on the market today.

CMS also published a final price for Overa of $752, which was benchmarked to the only proteomic test currently on the CLFS that uses biomarkers and an algorithm to produce a prognostic score. The price for Overa will be re-reviewed now that OVA1 is on the CLFS.

Links to multiple clinical studies showing OVA1’s strong performance compared to existing technologies, such as CA125 and ROMA, can be found on our website:

http://vermillion.com/providers/ova-1/clinical-validation-studies/.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases.  The company’s initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding the expected catalysts for Vermillion’s growth, the anticipated impact of the inclusion of OVA1 on the CLFS on Vermillion’s contracting efforts, plans to expand the ASPiRA Labs sales team and expected increases in the number of covered lives. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on Vermillion’s expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements, including changes to interpretations of existing laws and regulations and other factors that are described in Vermillion’s Form 10-K for the year ended December 31, 2016 and Form 10-Q for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission. Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
mwood@lifesciadvisors.com

Monday, November 20th, 2017 Uncategorized Comments Off on $VRML Release of Final CMS Reimbursement Rate for OVA1

$CLSN Publication of the Study of ThermoDox

Collaboration with University of Oxford to Execute a Clinical Trial Using Focused Ultrasound and ThermoDox® for Primary and Metastatic Liver Cancer

Presentation of TARDOX Study Phase I Findings at the Upcoming RSNA 2017 Annual Meeting

First Ever Study Evaluating ThermoDox® with Focused Ultrasound in Humans

LAWRENCEVILLE, N.J., Nov. 20, 2017 — Celsion Corporation (NASDAQ:CLSN) today announced publication of the manuscript, “Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours,” in the Journal of Therapeutic Ultrasound 2017 5:28.

The article describes the clinical trial design for the TARDOX Study. This proof of concept study was designed to demonstrate the safety and feasibility of targeted drug release and enhanced delivery of doxorubicin from thermally sensitive liposomes (ThermoDox®) triggered by mild hyperthermia induced by focused ultrasound in primary and metastatic solid liver tumors.

  • The primary outcome measures for the study was the direct quantification of the doxorubicin concentration before and after focused ultrasound (FUS) mediated hyperthermia from tumor biopsies, using high performance liquid chromatography (HPLC).
  • The secondary outcome measures for the study relate to the safety and feasibility of inducing controlled FUS-mediated targeted hyperthermia in the target tumor non-invasively in order to achieve ThermoDox® release.

The TARDOX Study, which is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, was carried out as a multi-disciplinary collaboration between Celsion, the Oxford University Institute of Biomedical Engineering (Prof. Constantin Coussios), the Oncology Clinical Trials Office (OCTO) and the Oxford University Hospitals NHS Foundation Trust (Prof. Fergus Gleeson, Radiology and Prof. Mark Middleton, Oncology). The first author is Dr. Paul Lyon (academic clinical fellow, Oxford University Hospitals NHS Foundation Trust) and the article is available online in the November 2, 2017 issue of the Journal of Therapeutic Ultrasound:

https://jtultrasound.biomedcentral.com/articles/10.1186/s40349-017-0104-0

“Both Celsion and Oxford believe there is significant potential when combining ThermoDox® with focused ultrasound to treat a broad range of malignancies, including primary liver cancer,” said Michael H. Tardugno, Celsion’s chairman, president and chief executive officer. “TARDOX, the ThermoDox®/Focused Ultrasound trial, is an important step in demonstrating that ultrasound-induced hyperthermia can enable the highly targeted delivery of chemotherapeutic agents to tumors non-invasively. This represents another unquestionable example confirming ThermoDox®’s mechanism of action in a clinical setting and further establishes that ThermoDox® may be used with multiple heating technologies allowing for successful targeting of a broad range of primary and metastatic solid tumors with high concentrations of chemotherapy.”

The Company also announced that an abstract for the TARDOX Study has been accepted for presentation at the Radiological Society of North America (RSNA) 2017 Annual Meeting which will take place from November 26, 2017 – December 1, 2017 at the McCormick Center in Chicago, IL.

  • The abstract, entitled “Clinical Results of a Phase I First in Man Study of Targeted Delivery of Lyso-thermosensitive Liposomal Doxorubicin by Extracorporeal Focused-Ultrasound Hyperthermia for Liver Tumours,” will be presented by Dr. Paul Lyon on Monday, November 27, 2017 at 11:40 am (local time) during Vascular Interventional (10-Liver Cancer) Session – Room E352.
  • The presentation will summarize clinical findings from all patients treated in the TARDOX Study, a Phase I clinical study of ThermoDox®, Celsion’s heat-activated liposomal encapsulation of doxorubicin, in combination with focused ultrasound to treat primary and metastatic liver cancer.

Professor Constantin-C. Coussios, senior author and Director of the Institute of Biomedical Engineering at the University of Oxford, commented, “This clinical program builds upon many years of experience with ultrasound-guided HIFU, as well as laboratory studies of ThermoDox® release by ultrasound, at our institution since 2007. This is the first study in humans to explore extra corporeally triggered drug release and targeted drug delivery in oncology. We look forward to exploring the combination of ThermoDox®, a well-characterized anti-cancer therapy triggered by heat, with focused ultrasound to cause hyperthermia, rather than ablation, non-invasively. We are excited by the potential of this combination to advance treatment within a significantly underserved population.”

About ThermoDox®

Celsion’s most advanced program is a heat-mediated, tumor-targeting drug delivery technology that employs a novel heat-sensitive liposome engineered to address a range of difficult-to-treat cancers. The first application of this platform is ThermoDox®, a lyso-thermosensitive liposomal doxorubicin (LTLD), whose novel mechanism of action delivers high concentrations of doxorubicin to a region targeted with the application of localized heat at 40°C, just above body temperature. In one of its most advanced applications, ThermoDox®, when combined with radiofrequency thermal ablation (RFA), has the potential to address a range of cancers. For example, RFA in combination with ThermoDox® has been shown to expand the “treatment zone” with a margin of highly concentrated chemotherapy when treating individual primary liver cancer lesions. The goal of this application is to significantly improve efficacy.

Celsion’s LTLD technology leverages two mechanisms of tumor biology to deliver higher concentrations of drug directly to the tumor site. The first: Rapidly growing tumors have leaky vasculature, which is permeable to liposomes and enables their accumulation within tumors. Leaky vasculature influences a number of factors within the tumor, including the access of therapeutic agents to tumor cells. Administered intravenously, LTLD is engineered to allow significant accumulation of liposomes at the tumor site at the time of radiofrequency ablation as these liposomes recirculate in the blood stream. The second: When the tumor tissue is heated to a temperature of 40°C or greater, the heat-sensitive liposome rapidly changes structure and the liposomal membrane selectively dissolves, creating openings that release the chemotherapeutic agent directly into the tumor and into the surrounding vasculature. Drug concentration increases as a function of the accumulation of liposomes at the tumor site, but only where the heat is present. This method targets only the tumor and the area related to tumor invasion, supporting precise drug targeting.

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company’s lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com (CLSN-LTSL/ThermoDox®)

About the NIHR Oxford Biomedical Research Centre

The NIHR Oxford Biomedical Research Centre (BRC) is based at the Oxford University Hospitals NHS Foundation Trust and run in partnership with the University of Oxford, funded by the National Institute for Health Research (NIHR).

The NIHR improves the health and wealth of the nation through research. Established by the Department of Health, the NIHR:

  • funds high quality research to improve health
  • trains and supports health researchers
  • provides world-class research facilities
  • works with the life sciences industry and charities to benefit all
  • involves patients and the public at every step

For further information, visit the NIHR website www.nihr.ac.uk.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion’s periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Celsion Investor Contact

Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com

Monday, November 20th, 2017 Uncategorized Comments Off on $CLSN Publication of the Study of ThermoDox

$OHGI Regains Full Compliance with NASDAQ Listing Requirements

LONDON, Nov. 20, 2017 —  One Horizon Group, Inc. (NASDAQ:OHGI) (“Company”) today announced that it received a letter from the NASDAQ Listing Qualifications Staff (“Staff”) on November 15, 2017, notifying the Company that it has regained compliance with The NASDAQ Capital Market’s minimum stockholders’ equity requirement under NASDAQ Listing Rules 5550(b)(1), 5550(b)(2) or 5550(b)(3) (“Rules”) for continued listing on The NASDAQ Capital Market and that Staff considers the matter closed.

On August 22, 2017, Staff notified the Company that it did not comply with the minimum $2.5 million stockholders’ equity, or $35 million market value of listed securities, or $500,000 of net income from continuing operations requirements for The NASDAQ Capital Market as required by the Rules.

However, based on the Form 10-Q for the period ended September 30, 2017, filed on November 14, 2017, reporting stockholders’ equity of $4,427,000, Staff has determined that the Company complies with the Rules and this matter is now closed.

On November 7, 2017, the Company announced that it received a letter from the Staff on November 6, 2017, notifying the Company that it had regained compliance with The NASDAQ Capital Market’s minimum bid price requirement under Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market and that Staff considers that matter closed as well.

Therefore, in accordance with the Staff letters of November 15, 2017, and November 6, 2017, the Company is in full compliance with the applicable NASDAQ Listing Requirements.

About One Horizon Group, Inc.

One Horizon Group, Inc. (NASDAQ:OHGI) is a reseller of secure messaging software for the growing gaming, security and education markets including in China and Hong Kong.  For more information on the Company please visit http://www.onehorizongroup.com/investors-overview/.

Darrow Associates Contacts for OHGI

Bernie Kilkelly
(516) 236-7007
bkilkelly@darrowir.com

Jordan Darrow
(512) 551-9296
jdarrow@darrowir.com

Monday, November 20th, 2017 Uncategorized Comments Off on $OHGI Regains Full Compliance with NASDAQ Listing Requirements

$ACST Development and Commercialization with Leading China Pharma Partner

LAVAL, QUÉBEC–(Nov. 20, 2017) – Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the company recently entered into a non-binding term sheet with a leading China-based pharmaceutical company. Completion of the transaction is subject to further negotiation and execution of a definitive agreement, which once signed would grant an exclusive license to the Chinese pharmaceutical company to commercialize CaPre in certain Asian countries, including China. With the high prevalence of hypertriglyceridemia in Asia, this potential partnership presents a significant opportunity for Acasti and CaPre.

If a definitive agreement is reached and signed, the term sheet contemplates that Acasti would receive an upfront payment of US$8 million upon signing, plus potential additional regulatory and commercial milestone payments in excess of US$125 million, and tiered double-digit royalties on net sales. The term sheet is preliminary and non-binding at this stage and the license, upfront payment, possible milestone payments, and royalties contemplated by it will only become operative if definitive documents are executed. It is possible that no definitive agreement will be reached or, if a definitive agreement is reached, that its terms or conditions may differ from those described above.

About CaPre® (omega-3 phospholipid)

Acasti’s prescription drug candidate, CaPre, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. Its omega-3s, principally EPA and DHA, are either “free” or bound to phospholipids that allows for better absorption into the body. This allows for enhanced bioavailability and EPA and DHA blood levels compared to the “esterified” fish-oil omega-3 options such as LOVAZA.

About Acasti Pharma

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company’s strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. For more information, visit www.acastipharma.com.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Forward-looking information in this press release includes, but is not limited to, information or statements about whether a definitive agreement will be negotiated and executed, whether the upfront payment or any milestone payments will be received and the significance of market opportunities for the treatment of hypertriglyceridemia in Asia.

The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement, the “Cautionary Note Regarding Forward-Looking Information” section contained in Acasti’s latest annual report on Form 20-F and most recent management’s discussion and analysis (MD&A), which are available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar/shtml, and on the investor section of Acasti’s website at www.acastipharma.com. All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in Acasti’s public securities filings with the Securities and Exchange Commission and the Canadian securities commissions, including Acasti’s latest annual report on Form 20-F and most recent MD&A.

Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Acasti Contact:
Jan D’Alvise, Chief Executive Officer
450-686-4555
info@acastipharma.com
www.acastipharma.com

Media Contact:
Jessica Dyas, Canale Communications
619-849-5385
jessica@canalecomm.com

Investor Relations Contact:
Glen Akselrod, Bristol Capital Ltd.
(905) 326-1888 ext 10
glen@bristolir.com

Monday, November 20th, 2017 Uncategorized Comments Off on $ACST Development and Commercialization with Leading China Pharma Partner

$IGC Reports Second Quarter 2018 Financial Results and Operational Highlights

BETHESDA, Md., Nov. 20, 2017 — India Globalization Capital, Inc. (NYSE American:IGC), today reported financial results for the second quarter ended September 30, 2017 and provided an overview of recent operational highlights.

“Our initial focus on the canna-pharmaceutical front is on Alzheimer’s, America’s most expensive disease.  In 2017, the direct cost of treatment for Alzheimer’s and other dementias is projected to cost the U.S. approximately $259 billion.  In the U.S., roughly 5.3 million individuals suffer from the disease and the number is expected to double over the next 20 years.  Worldwide, approximately 43 million individuals suffer from the disease, and there is no cure.  Independent of our longer-term FDA clinical trial process, our near-term goal is to commercialize our liquid formulation for Alzheimer’s as a Complimentary and Alternative Medicine (CAM) sold through licensed medical cannabis dispensaries in the U.S., and internationally in Canada and Germany,” stated Ram Mukunda, CEO of IGC.

In May 2017, we acquired exclusive rights to a patent filed by the University of South Florida Research Foundation entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease”.  It is believed that in Alzheimer’s disease two types of legions in the brain are implicated in the pathogenesis of the disease: (1) senile plaque composed of amyloid beta peptides (Aβ plaque), and (2) neurofibrillary tangles, composed of highly phosphorylated Tau protein.  Amyloid Precursor Protein (APP), on the surface of neurons, is normally cleaved by enzymes to free up Aβ peptide composed of 36-43 amino acids that is then cleared by the body. In patients with Alzheimer’s, an imbalance causes Aβ to be unregulated, resulting in the abnormal buildup into insoluble fibrils depositing as senile plaques. Aβ monomers aggregate to form oligomers and then into fibril Aβ. It is believed that extracellular misfolded oligomers are toxic to nerve cells. IGC’s Alzheimer’s drug candidate, IGC-AD1, has been shown to work through a molecular pathway that allows IGC-AD1 to: 1) modulate Aβ protein production, 2) inhibit Aβ protein aggregation, 3) reduce Tau phosphorylation, 4) enhance mitochondria function, and 5) possibly help redirect the immune system, with none of the side effects commonly associated with cannabis. Based on these and other studies, we expect to bring IGC-AD1 to market in early 2018, with the hope of bringing much needed relief to Alzheimer’s patients.

In addition, we made progress on our six provisional patent filings in the phytocannabinoid-based combination therapy space for the indications of pain, medical refractory epilepsy, and cachexia. The table below provides a status of the patent filings:

Indication Provisional
Filing
PCT Filing Subsequent Activity
Pain (IGC-501) 9/16/14 9/16/15 US National Case Filed – 6/15/16
Seizures (IGC-502) 6/15/15 6/14/16 US National Case Filed – 6/15/16
Seizures (IGC-503) 4/1/15 4/1/16 PCT Application Published- 10/6/16
Eating Disorders (IGC-504) 8/12/15 8/11/16 US and National Filing Anticipated 2/12/18
Seizures (IGC-505) 6/15/16 6/15/16 US National Filing Anticipated 12/15/18
Eating Disorders (IGC-506) 2/28/17 Anticipated- 2/28/18 US and National Filing Anticipated 8/28/19
Alzheimer’s (IGC-AD1) 7/30/2015 Anticipated -2018 US and National Filing Anticipated in 2018

Results of Operations

Revenue – We have two lines of business: (a) “legacy”, consisting of rental of heavy equipment, commodities trading, and real estate management, and (b) “canna-pharmaceutical”. Total revenue from the legacy business was $235,648 for the three months ended September 30, 2017 as compared to $162,163 for the three months ended September 30, 2016.  The increase was primarily driven by increased volume of business.

Cost of Revenue (excluding depreciation) – Cost of revenue for the three months ended September 30, 2017 was $163,170 as compared to $90,534 for the three months ended September 30, 2016.  The increase in cost of revenue stems from an increase in the volume of the legacy business.

Selling, General and Administrative – Selling, general and administrative expenses were $331,146 for the three months ended September 30, 2017 as compared to $339,585 for the three months ended September 30, 2016.

Depreciation – The depreciation expense was approximately $4,344 in the three months ended September 30, 2017 as compared to $97,842 in the three months ended September 30, 2016.  The decrease in depreciation is from the curtailment of the iron-ore mining business in China.

Interest and other financial expenses – The interest expense and other financial expenses for the three months ended September 30, 2017 were approximately $40,832 as compared to approximately $51,410 for the three months ended September 30, 2016.  Most of the interest is paid with common shares of the Company and is therefore non-cash.

Other income/(loss) – Other income was $(144) for the three-month period ended September 30, 2017 as compared to $11,985 in September 30, 2016. Other income includes income from the supply of skilled operators for the legacy heavy equipment rental business.

Consolidated Net Income/(loss) – In the three months ended September 30, 2017, the Company reported a GAAP net income loss of $303,804 and a GAAP EPS loss of $0.01 compared to a GAAP net income loss of $583,871 and a GAAP EPS loss of $0.02 for the three months ended September 30, 2016.

At the end of September 30, 2017, our cash and cash equivalents along with restricted cash was $597,026 and working capital of $803,769. We expect to raise money for the canna-pharmaceutical business, specifically to immediately begin marketing IGC-AD1.

About IGC:
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA.

For more information please visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements:
Please see forward-looking statements and risk factors as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact:
Claudia Grimaldi
301-983-0998

FINANCIAL TABLES TO FOLLOW

INDIA GLOBALIZATION CAPITAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(All amounts in USD, except number of shares and per share amounts)
As of
30-Sept-17 31-March-17
(unaudited) (audited)
ASSETS
Current assets:
Cash and cash equivalents $ 597,026 $ 538,029
Accounts receivable, net of allowances 1,033,608 752,926
Prepaid expenses and other current assets 393,579 410,408
Short-term investments 1,880,000
Total current assets $ 2,024,213 $ 3,581,363
Goodwill 198,169 198,169
Intangible assets 111,691
Property, plant and equipment, net 953,257 953,936
Investments in affiliates 773,111 773,111
Investments-others 5,240,166 5,238,003
Other non-current assets 691,745 539,720
Total long-term assets $ 7,968,139 $ 7,702,939
Total assets $ 9,992,352 $ 11,284,302
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Trade payables 613,131 416,532
Accrued expenses 197,716 181,465
Other current liabilities 409,597 691,714
Total current liabilities $ 1,220,444 $ 1,289,711
Long-term borrowings 350,794 452,080
Loans – others 399,726 392,226
Notes payable 1,800,000 1,800,000
Total non-current liabilities $ 2,550,520 $ 2,644,306
Total liabilities $ 3,770,964 $ 3,934,017
Stockholders’ equity:
Common stock — $.0001 par value; 150,000,000 shares authorized; 28,272,667 issued and outstanding as of March 31, 2017 and 28,005,272 issued and outstanding as of September 30, 2017. $ 2,801 $ 2,827
Additional paid-in capital 60,974,013 61,413,533
Accumulated other comprehensive income (2,058,702 ) (2,047,780 )
Retained earnings/(Deficit) (52,687,870 ) (52,009,459 )
Total equity attributable to Parent $ 6,230,242 $ 7,359,121
Non-controlling interest $ (8,854 ) $ (8,836 )
Total stockholders’ equity $ 6,221,388 $ 7,350,285
Total liabilities and stockholders’ equity $ 9,992,352 $ 11,284,302

See accompanying Notes to Consolidated Financial Statements below in this report and Notes to the Audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.

INDIA GLOBALIZATION CAPITAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
All amounts in USD except
share data
All amounts in USD except
share data
Three months ended
September 30,
Six months ended
September 30,
2017 2016 2017 2016
Revenues $ 235,648 $ 162,163 $ 288,573 $ 237,563
Cost of revenues (excluding depreciation) (163,170 ) (90,534 ) (170,051 ) (154,589 )
Selling, general and administrative expenses (331,146 ) (339,585 ) (709,960 ) (636,802 )
Depreciation (4,344 ) (97,842 ) (10,309 ) (195,514 )
Loss on investments/associates /joint ventures (183,835 ) (183,835 )
Operating income (loss) $ (263,012 ) $ (549,633 ) $ (601,747 ) $ (933,177 )
Interest expense (40,832 ) (51,410 ) (85,378 ) (89,956 )
Interest income 100 114 101 114
Other income, net/(loss) (144 ) 11,985 8,210 13,740
Income before income taxes and minority interest attributable to non-controlling interest $ (303,888 ) $ (588,944 ) $ (678,814 ) $ (1,009,279 )
Income taxes benefit/(expense)
Net income/(loss) $ (303,888 ) $ (588,944 ) $ (678,814 ) $ (1,009,279 )
Non-controlling interests in earnings of subsidiaries (84 ) (5,073 ) (403 ) (11,239 )
Net income/(loss) attributable to common stockholders $ (303,804 ) $ (583,871 ) $ (678,411 ) $ (998,040 )
Earnings/(loss) per share attributable to common stockholders:
Basic $ (0.01 ) $ (0.02 ) $ (0.02 ) $ (0.04 )
Diluted $ (0.01 ) $ (0.02 ) $ (0.02 ) $ (0.04 )
Weighted-average number of shares used in computing earnings per share amounts:
Basic 27,355,826 23,636,403 27,355,826 23,636,403
Diluted 29,051,771 23,636,403 29,051,771 23,636,403

See accompanying Notes to Consolidated Financial Statements below in this report and Notes to the Audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.

Monday, November 20th, 2017 Uncategorized Comments Off on $IGC Reports Second Quarter 2018 Financial Results and Operational Highlights

$CIIX CBD Biotech Enterprise Partners with Chinese Beauty Influencer

ChineseInvestors.com (OTCQB: CIIX) said today that its foreign enterprise, CBD Biotechnology Co. Ltd., has partnered with The Godfather of Beauty for the launch of its “CBD Magic Hemp Series” skincare line on China’s largest e-commerce retailer Alibaba. There were over 40,000 views during the first broadcast of “China Taobao Live Broadcasting Celebrity Show,” with more than 91 units from the CBD Magic Hemp Series skincare line purchased minutes into the launch. “The success of the initial launch of the CBD Magic Hemp Series skincare line on Taobao solidifies our belief that Chinese consumers recognize that the anti-inflammatory agents and anti-oxidants contained in hemp-extract can have positive effects on the skin,” ChineseInvestors.com CEO Warren Wang stated in the news release.

To view the full article, visit: http://cnw.fm/ZpO5S

About ChineseInvestors.com

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products. For more information, visit www.ChineseInvestors.com.

More from CannabisNewsBreaks

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Monday, November 20th, 2017 Uncategorized Comments Off on $CIIX CBD Biotech Enterprise Partners with Chinese Beauty Influencer

$LE Offers Chance To Be Santa For a Day

Chance to Win $10,000, a $5,000 Donation to Charity of Choice, Sacks of Presents and Lands’ End Gift Cards

DODGEVILLE, Wis., Nov. 17, 2017 — The holiday season is here and Lands’ End will once again embrace the spirit of giving through the Santa for a Day campaign. The generous giving initiative will award sacks of presents and an abundance of gift cards as well as offer incredible product promotions and the chance to personally win $10,000 through the Santa for a Day sweepstakes.

“Santa has always represented the true spirit of giving and through the Santa for a Day campaign we are able to extend that magic and give others the chance to be as generous as our old friend from the North Pole this holiday season,” said Matt Trainor, SVP of Brand Creative at Lands’ End. “Whether it’s through incredible personalized gifts and unique promotions, an engaging social initiative or events in local markets where the search is on for ‘Santas,’ we are on a mission to celebrate the spirit of giving this season and continue to be ‘Holiday Makers’.”

Santa Goes Social: #santaforaday
Aspiring gift givers can participate daily in the #santaforaday social campaign from November 28 – December 17 on Twitter. Each day a unique Santa interview question will be asked at @LandsEnd; participants can answer using #santaforaday and #LandsEndHoliday to be entered for a chance to win a $100 Lands’ End gift card. Winners will be selected at random. The gift card prizes are an effort to help aspiring Santas fulfill gift lists this holiday season.

Santa for a Day in Minneapolis and Chicago Area
Lands’ End will spread holiday cheer in Minneapolis and the Chicago area by offering the chance to be Santa for a Day. Event attendees in each city will be invited to call the Santa Hotline in an iconic red phone booth and speak with Santa for a chance to be selected as a Santa for a Day.  Selected “Santas” from each city will each receive a sack of presents and have the chance to share in the spirit of giving.

Win and Give Santa for a Day Sweepstakes
Lands’ End is also offering one lucky winner the chance to truly be Santa for a Day through a holiday sweepstakes. Now through December 17, 2017, everyone can enter for a chance to win $10,000 in cash, as well as $5,000 for a charity of choice (to be approved by Lands’ End).  To enter daily, fill out the form at landsend.com/santaforaday.

Santa For A Day Instant Win
From now until Dec. 17, 2017, shoppers can also play the Lands’ End Santa for a Day Instant Win Game Sweepstakes for a chance to win a $1,000 Lands’ End gift card each week. For more information or to enter visit landsend.com/santaforaday.

About Lands’ End, Inc.
Lands’ End, Inc. (Nasdaq: LE) is a leading multi-channel retailer of clothing, accessories, footwear and home products. We offer products through catalogs, online at www.landsend.com and affiliated specialty and international websites, and through retail locations, primarily at Lands’ End Shops at Sears® and standalone Lands’ End Stores. We are a trusted American lifestyle brand with a passion for quality, legendary service and real value, and seek to deliver timeless style for men, women, kids and the home.

URLs: www.landsend.com/santaforaday
www.landsend.com/newsroom
Friday, November 17th, 2017 Uncategorized Comments Off on $LE Offers Chance To Be Santa For a Day

$AMRS DSM Expands Strategic Alliance, Acquires Brazilian Production Facility

HEERLEN, The Netherlands and EMERYVILLE, Calif., Nov. 17, 2017 — Royal DSM (AEX:DSM.AS), a global science-based company active in health, nutrition and materials and Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that they have enhanced their strategic alliance through the sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’ high-volume products.

Total consideration for Amyris Brasil Ltda (which owns and operates the Brotas 1 production facility), intellectual property related to farnesene (a bio-based key intermediate for many applications) and an additional value share arrangement over a three-year period amounts to US$ 96 million. In addition to the consideration upfront there is potential for a future value share in line with Amyris’ business model.

DSM will continue existing supply-agreements to Amyris and other parties. DSM will also supply Amyris with specialty compounds until it realizes its Brotas 2 specialties production facility. Amyris is accelerating the construction of its second facility dedicated to specialty products while maintaining the manufacturing process development and business support capability located in Campinas, Brazil.

Subject to customary conditions, the transaction is expected to close in the next few months.

With the acquisition of the Brotas 1 facility, DSM adds a state-of-the-art biotechnology-based production site in Brazil to its global network, with abundant availability of sustainable raw materials (sugar cane), securing production capacity for its rich pipeline of sustainable and bio-based solutions. Having broad experience in operating large-scale fermentation plants, DSM will optimize the operational performance of the site.

The strategic alliance between DSM and Amyris started in May 2017 with an equity investment by DSM in Amyris, and has since been expanded with several significant product development collaborations.

The sale of the Brotas 1 facility, which was designed to produce high volumes of farnesene, together with the creation of a long-term production relationship for high-volume farnesene-based intermediates will enable Amyris to focus on its core strength of developing breakthrough bioscience technologies through a portfolio approach that continues to target key markets, as well as the production of specialty products.

“Following our equity investment in Amyris and subsequent product development cooperations, I am pleased that we can add a state-of-the-art fermentation-based production facility to our network. Our know-how in fermentation, downstream process development and large-scale manufacturing will allow us to further improve the operational performance of the facility while further strengthening our strategic alliance with Amyris,” said Chris Goppelsroeder, President & CEO of DSM Nutritional Products.

“We are very pleased with the continued expansion of our strategic alliance with DSM,” said John Melo, Amyris President & CEO. “This manufacturing partnership and the sale of our Brotas 1 factory allows us to accelerate the development and manufacturing of specialty, high-performance ingredients. We are building a specialty plant at Brotas (Brotas 2) and also expect to complete our São Martinho plant to focus on sweeteners. The combination of these actions provides us the manufacturing footprint to meet our current demand through the next 3-5 years and to manage this within our funding constraints.”

Continued Melo, “This transaction completes a planned shift from operating a plant originally designed to produce high volumes of farnesene, to producing an expanding number of high-value, specialty ingredients. This shift will allow Amyris to improve returns and cash flows in order to continue to provide sustainable growth for Amyris and its partners.”

DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.

DSM Forward-Looking Statements
This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

Amyris Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as expected upfront consideration to Amyris in the transaction as well as future value share payments, the anticipated closing of the transaction, including the timing thereof, the expected continuation of existing supply agreements with Amyris and other parties, the anticipated supply of Amyris’s specialty compounds, the expected construction of the proposed Brotas 2 facility, the anticipated development and manufacturing of specialty ingredients, the expected construction of a proposed plant focused on sweeteners, anticipated ability to meet current and future demand, and expected improvements in returns, cash flows and growth), that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris’s liquidity and ability to fund operating and capital expenses, timing and execution risks associated with manufacturing, uncertainty regarding consummating proposed transactions, including the timing thereof, and growth in sales, potential delays or failures in development, production and commercialization of products, risks related to Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on August 14, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.

For more information:

DSM Corporate Communications
Herman Betten
tel. +31 (0) 45 578 2017
e-mail media.contacts@dsm.com

Amyris, Inc.
Peter DeNardo
tel.: +1 (510) 740-7481
e-mail: investor@amyris.com
pr@amyris.com

DSM Investor Relations
Dave Huizing
tel.: +31 (0) 45 578 2864
e-mail: dave.huizing@dsm.com

Friday, November 17th, 2017 Uncategorized Comments Off on $AMRS DSM Expands Strategic Alliance, Acquires Brazilian Production Facility

$STKS Announces Closing of Strategic Financing

NEW YORK

Mr. Kin Chan Elected to the Board of Directors

The ONE Group Hospitality, Inc. (NASDAQ: STKS) today announced the closing of a strategic financing with Elevated Returns, LLC and Argyle Street Management Limited and another accredited investor to further strengthen the Company’s balance sheet and fund strategic initiatives. The Company appointed Mr. Kin Chan to the board of directors effective upon the closing of the financing.

Pursuant to a securities purchase agreement entered into on November 15, 2017, the investors purchased from the Company 1,750,000 shares of common stock at a price of $1.50 per share in a registered direct offering, resulting in total gross proceeds of $2.625 million. In a concurrent private placement, the Company also issued unregistered warrants to the investors to purchase up to an aggregate of 875,000 shares of common stock with an exercise price of $1.63 per share, which was the Nasdaq consolidated closing bid price per share on November 14, 2017. The warrants will be exercisable six months following the closing date and will expire five years from the date they become exercisable.

The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-203429), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on May 22, 2015. The warrants and shares issuable upon exercise of the warrants were offered in a concurrent private placement and have not been registered under the Securities Act of 1933, as amended. The Company has agreed to file a registration statement on Form S-1 with the SEC covering the resale of the shares of common stock issuable upon exercise of the warrants.

Manny Hilario, Chief Executive Officer of The ONE Group Hospitality, noted, “We are excited to announce this investment by Elevated Returns and Argyle Street Management Limited, as both firms have a strong history of investments in the hospitality industry. They also bring significant international experience, particularly throughout Asia, which is one of the largest potential growth opportunities we see for the STK brand. With Mr. Kin Chan being based in Hong Kong, we will now have representation at the Board level in the Far East to enable us to start to focus on expanding into that very lucrative market. This investment by Elevated Returns and Argyle Street Management Limited also strengthens our balance sheet and positions us well as we continue to grow our brand through global licensing opportunities.”

Mr. Kin Chan, founding shareholder and Chief Investment Officer of Argyle Street Management Limited, stated, “This investment demonstrates our confidence in The ONE Group Hospitality and the business strategy the management team is executing. We believe The ONE Group Hospitality has a global growth opportunity and we look forward to working with the Company.”

Effective upon the closing of the financing, Mr. Kin Chan was appointed to the Company’s Board of Directors replacing Nicholas Giannuzzi. Mr. Chan is also the Chairman of TIH Limited and a director of OUE Limited, both listed on the Singapore Exchange; an Independent Non-Executive Director of Mount Gibson Iron Limited, an Australia-listed mining company; and nonexecutive director of CITIC Resources Holdings Limited, a company listed in Hong Kong. Mr. Chan was an Executive Director at Goldman, Sachs & Co. where he worked in Hong Kong, New York and Singapore from 1992 to 1999. Mr. Chan holds an AB from Princeton University and MBA from Wharton School of the University of Pennsylvania where he was a Palmer Scholar.

Jonathan Segal, the Company’s Chairman, noted, “We are pleased to appoint Mr. Kin Chan to our board. Mr. Chan adds significant international hospitality experience and he has many strong relationships within the hospitality segment. As we focus on global growth through licensing opportunities, we believe that his vast experience could be a strong asset to our board.”

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About The ONE Group

The ONE Group Hospitality, Inc. (“The ONE Group”) (Nasdaq:STKS) is a global hospitality company that develops and operates upscale, high-energy restaurants and lounges and provides hospitality management services for hotels, casinos and other high-end venues both nationally and internationally. The ONE Group’s primary restaurant brand is STK, a modern twist on the American steakhouse concept with locations in major metropolitan cities throughout the U.S. and Europe. The ONE Group’s food and beverage hospitality services business, ONE Hospitality, provides the development, management and operations for premier restaurants and turn-key food and beverage services within high-end hotels and casinos. Additional information about The ONE Group can be found at www.togrp.com.

Cautionary Statement on Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements, including but not limited to, (1) our ability to open new restaurants and food and beverage locations in current and additional markets, grow and manage growth profitably, maintain relationships with suppliers and obtain adequate supply of products and retain our key employees; (2) factors beyond our control that affect the number and timing of new restaurant openings, including weather conditions and factors under the control of landlords, contractors and regulatory and/or licensing authorities; (3) in the case of our strategic review of operations, our ability to successfully improve performance and cost, realize the benefits of our marketing efforts, and achieve improved results as we focus on developing new management and license deals; (4) our ability to enter into licensing agreements; (5) changes in our management team; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) other risks and uncertainties indicated from time to time in our filings with the SEC, including our Annual Report on Form 10-K filed on April 5, 2017.

Investors are referred to the most recent reports filed with the SEC by The ONE Group Hospitality, Inc. Investors are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.

Investors:
ICR
Michelle Michalski, 646-277-1224

Friday, November 17th, 2017 Uncategorized Comments Off on $STKS Announces Closing of Strategic Financing

$TOUR Management Change and Preliminary Results for the Third Quarter of 2017

NANJING, China, Nov. 17, 2017  — Tuniu Corporation (NASDAQ: TOUR) (“Tuniu” or the “Company”), a leading online leisure travel company in China, today announced that Mr. Haifeng Yan, co-founder, President and Chief Operating Officer, and Mr. Conor Chia-hung Yang, Chief Financial Officer, will resign from their positions with the Company, effective November 17, 2017, for personal reasons. Mr. Yan will continue to serve as a member of the board of directors of the Company and Mr. Yang will serve as a senior consultant to the Company.

Tuniu has promoted Ms. Maria Yi Xin from Vice President of the Company to assume the position of Chief Financial Officer. Ms. Xin joined Tuniu in 2013 and has over 10 years of experience in corporate finance and capital markets with US-listed companies. While at Tuniu, Ms. Xin has held various key roles at the Company such as Vice President of investor relations, strategic investments and international media. Prior to Tuniu, Ms. Xin worked in equity research at China Renaissance, a leading financial institution in China. Prior to China Renaissance, Ms. Xin worked at E-Commerce China Dangdang Inc., a leading business-to-consumer e-commerce company in China then listed on the NYSE, and at New Oriental Education and Technology Group Inc. (NYSE: EDU), the largest provider of private educational services in China. Ms. Xin received Bachelor’s degrees in economics and law from Nankai University.

Mr. Dunde Yu, co-Founder, Chairman and Chief Executive Officer of the Company, said, “We would like to thank Mr. Yan and Mr. Yang for their contributions to Tuniu over the years. Although they will be stepping away from day-to-day operations, they will continue to work closely with Tuniu on the company’s strategy and business development. We are also very delighted to promote Ms. Xin to the role of Chief Financial Officer. Since joining Tuniu, Ms. Xin has been a key member of our team and has helped Tuniu in many areas. Together, we look forward to bringing Tuniu to new heights.”

Third Quarter 2017 Preliminary Results

For the third quarter of 2017, Tuniu currently estimates that its total net revenues will be in the range of RMB800.0 million to RMB810.0 million, above the previous guidance of RMB761.5 million to RMB787.7 million. Tuniu estimates that its non-GAAP net income will be in the range of RMB35.0 million to RMB40.0 million, as compared with a non-GAAP loss during the third quarter of 2016.

Ms. Maria Yi Xin, Chief Financial Officer, said, “We expect solid performance for the third quarter as our core leisure travel business continues to benefit from China’s growing demand for leisure travel. On the business operations side, Tuniu is leveraging its established brand, dynamic technology infrastructure and extensive supply chain to achieve greater efficiency. We will continue to scale our operation as the leader in China’s online leisure travel market and to unlock value for our shareholders.”

Tuniu to Report Third Quarter 2017 Financial Results on November 27, 2017 U.S. Time

Additional information regarding Tuniu’s results for the third quarter of 2017 will be available when Tuniu reports its quarterly results on November 27, 2017, at which time management will discuss the Company’s financial and business performance in more detail.

Tuniu’s management will hold an earnings conference call at 8:00 am U.S. Eastern Time on November 27, 2017 (9:00 pm Beijing/Hong Kong Time on November 27, 2017).

Listeners may access the call by dialing the following numbers:

US +1-888-346-8982
Hong Kong 800-905945
China 4001-201203
International +1-412-902-4272
Conference ID: Tuniu Q3 2017 Earnings Call

A telephone replay will be available one hour after the end of the conference call through December 4, 2017. The dial-in details for the replay are as follows:

US +1-877-344-7529
International +1-412-317-0088
Replay Access Code: 10114447

Additionally, a live and archived webcast of this conference call will be available at http://ir.tuniu.com/.

About Tuniu

Tuniu (Nasdaq:TOUR) is a leading online leisure travel company in China that offers a large selection of packaged tours, including organized and self-guided tours, as well as travel-related services for leisure travelers through its website tuniu.com and mobile platform. Tuniu has over 1,800,000 stock keeping units (SKUs) of packaged tours, covering over 400 departing cities throughout China and all popular destinations worldwide. Tuniu provides one-stop leisure travel solutions and a compelling customer experience through its online platform and offline service network. For more information, please visit http://ir.tuniu.com.

Safe Harbor Statement

This press release contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Tuniu may also make written or oral forward-looking statements in its reports filed with or furnished to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about Tuniu’s beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but are not limited to the following: Tuniu’s goals and strategies; the growth of the online leisure travel market in China; the demand for Tuniu’s products and services; its relationships with customers and travel suppliers; the Company’s ability to offer competitive travel products and services; Tuniu’s future business development, results of operations and financial condition; competition in the online travel industry in China; relevant government policies and regulations relating to the Company’s structure, business and industry; and the general economic and business condition in China and elsewhere. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is current as of the date of the press release, and Tuniu does not undertake any obligation to update such information, except as required under applicable law.

For investor and media inquiries, please contact:

China

Mary Chen
Investor Relations Director
Tuniu Corporation
Phone: +86-25-8685-3178
E-mail: ir@tuniu.com

Friday, November 17th, 2017 Uncategorized Comments Off on $TOUR Management Change and Preliminary Results for the Third Quarter of 2017

$MICT Receives $1,900,000 New Order for its TREQ®-317 On Board Computer

Order from a leading ELD compliant U.S. telematics provider – Serves growing $10 billion mobile resources management market

MONTVALE, N.J., Nov. 17, 2017 — Micronet Enertec Technologies, Inc. (NASDAQCM: MICT), (the “Company”), announced today that its Mobile Resource Management (MRM) subsidiary, Micronet Inc., has received a purchase order from a current customer, a leading U.S. telematics service provider, valued at $1,900,000 for its TREQ®-317.

In the last 7 months Micronet has received orders for an aggregate of over $14 million, which it believes continues to demonstrate the strong demand for Micronet’s state of the art technological solutions for the telematics and the electronic logging device (ELD) market.

The TREQ®-317 is a rugged Android™ based fix-mount on board computer offering advanced functionality at a competitive price. Micronet’s TREQ®-317 enables its users to provide real-time monitoring of both vehicle and driver activity and is fully compliant with ELD regulations.

“We are very pleased to continue working with our valued customers. We believe that new orders from current customers are a clear indication of the value our products deliver in the MRM space. We believe that the continued and increasing demand for our advanced Android based computing systems supports Micronet in expanding its product offerings and becoming a leading provider in the rapidly expanding MRM/telematics market,” said David Lucatz, Chief Executive Officer of Micronet Enertec Technologies, Inc.

About Micronet Enertec Technologies, Inc.

Micronet Enertec Technologies, Inc. (NASDAQCM: MICT) provides high tech solutions for severe environments and the battlefield, including missile defense technologies for Aerospace & Defense and rugged mobile devices for the growing commercial MRM market. MICT designs, develops, manufactures and supplies customized military computer-based systems, simulators, automatic test equipment and electronic instruments, addressing the defense industry. Solutions and systems are integrated into critical systems such as command and control, missile fire control, maintenance of military aircraft and missiles for the Israeli Air Force, Israeli Navy and by foreign defense entities.  MICT’s MRM division develops, manufactures and provides mobile computing platforms for the mobile logistics management market in the U.S., Europe and Israel. American-manufactured systems are designed for outdoor and challenging work environments in trucking, distribution, logistics, public safety and construction.

Forward-looking Statements

This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. These forward-looking statements include, but are not limited to, those statements regarding the Company’s belief that new orders from current customers are a clear indication of the value its products deliver in the MRM space and demonstrate the strong demand for Micronet’s state of the art technological solutions for the telematics and the ELD market, as well as the Company’s belief that the continued and increasing demand for its advanced Android based computing systems supports Micronet in expanding its product offerings and becoming a leading provider in the rapidly expanding MRM/telematics market. Such forward-looking statements and their implications involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. The forward-looking statements contained in this press release are subject to other risks and uncertainties, including those discussed in the “Risk Factors” section and elsewhere in the Company’s annual report on Form 10-K for the year ended December 31, 2016 and in subsequent filings with the Securities and Exchange Commission. Except as otherwise required by law, the Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Friday, November 17th, 2017 Uncategorized Comments Off on $MICT Receives $1,900,000 New Order for its TREQ®-317 On Board Computer

$AFAM & $LHCG In-Home Healthcare Services Merger of Equals

  • National platform enables greater service and continuity across continuum of care
  • Well-positioned to lead the transition to value-based reimbursement through the highest quality and patient satisfaction
  • Immediately accretive for the shareholders of each company
  • $25 million in run-rate cost synergies identified
  • Diversification of services and expansion of geographic footprint creates in-home healthcare provider and joint venture partner of choice for leading hospitals and health systems
  • Well-capitalized balance sheet for continued growth through acquisitions
  • Multi-channel growth opportunities accelerate organic growth, expand joint venture relationships and extend service lines

LAFAYETTE, La. and LOUISVILLE, Ky., Nov. 16, 2017 — LHC Group, Inc. (NASDAQ:LHCG) and Almost Family, Inc. (NASDAQ:AFAM) announced today that they have agreed to combine in an all-stock merger of equals transaction pursuant to a definitive merger agreement unanimously approved by the Boards of Directors of each company.

The merger will create a nationwide provider of in-home healthcare services with a long track record of successfully partnering with hospitals and health systems led by the most experienced management team steeped in home health. The combined company will have 781 locations in 36 states with more than 31,000 employees and revenue of $1.8 billion and Adjusted EBITDA of approximately $145 million for the trailing 12-month period ended September 30, 2017.

Compelling Strategic Rationale

  • Industry Leadership: Creates the leading in-home healthcare company in the United States, with a large, national footprint and diversified lines of service as well as Centers for Medicare & Medicaid Services (CMS) Star ratings that outpace the industry. The combined company is well-positioned to lead the industry’s transition to value-based reimbursement and highly coordinated care.
  • Accelerated Growth: The creation of a comprehensive in-home healthcare solution with home health, hospice and personal care services sets the stage for new channels of organic growth throughout the existing footprint. The combined company will be positioned as the preferred in-home healthcare partner to current and potential hospital joint venture partners as well as referral sources. A significant pipeline of joint ventures, extensions of existing relationships and acquisitions is expected to accelerate revenue growth.
  • Immediate Accretion: The merger is expected to be immediately accretive to adjusted earnings per diluted share for both companies, and to generate identified pre-tax run-rate cost synergies of $25 million.
  • Balance Sheet Flexibility: Combined gross leverage is expected to be 1.5x based on combined trailing 12-month 2017 Adjusted EBITDA as of September 30, 2017, pro forma for $25 million in cost synergies, which provides additional capacity to pursue new acquisition opportunities.
  • Strong Cultural Fit and Shared Vision: A history of senior leadership collaboration within the in-home healthcare industry and a shared vision to shape the evolution of the U.S. healthcare delivery system to value-based reimbursement set the stage for an integration of naturally synergistic organizations. The ability to leverage technology to extend scale and share best practices among two industry leaders in quality and patient satisfaction creates a localized provider with an unrivaled commitment to delivering patient-centered care in the home.
  • Industry Leading Management Team: The combined company is led by a management team with strong operational expertise, a proven track record of developing joint ventures with leading hospitals and health systems and a history of successful, efficient capital deployment.

Transaction Details
Under terms of the transaction, Almost Family shareholders will receive 0.9150 shares of LHC Group for each existing Almost Family share. Upon closing of the transaction, LHC Group shareholders will own 58.5% and Almost Family shareholders will own 41.5% of the combined company. The stock issuance in the merger is expected to be tax-free to shareholders of both companies. The transaction, which is expected to be completed in the first half of 2018, is subject to the receipt of regulatory approvals and other customary closing conditions as well as the approval of shareholders of both LHC Group and Almost Family.

The combined company will continue to trade on NASDAQ under the ticker symbol, “LHCG.” William Yarmuth, current chairman and chief executive officer of Almost Family, will remain as a special advisor to the combined company, while Steve Guenthner, current president and principal financial officer of Almost Family, will be named chief strategy officer. Keith Myers, current chairman and chief executive officer of LHC Group, will be named chairman and chief executive officer of the combined company, while Donald Stelly will be named president and chief operating officer and Joshua Proffitt will be named chief financial officer. The Board of Directors will be comprised of ten members, six of which (including Mr. Myers and Lead Independent Director Billy Tauzin) will be current LHC Group directors and four of which will be Almost Family directors. The combined companies’ Home Office will remain in Lafayette, La., and Personal Care Services, Healthcare Innovations and other support services will continue to operate out of Louisville, Ky.

Commenting on the announcement, Keith G. Myers, LHC Group’s chairman and CEO, said, “William Yarmuth and I have worked closely together on many of the important issues our industry has faced over the years, including the most recent home health advocacy with CMS, Office of Management and Budget and Congress. Almost Family shares our vision for making a difference in the communities we serve by delivering quality, outcomes-focused, patient-centered care to the most vulnerable in society. This merger is truly a transformative event for both our companies and our patients nationwide and a unique opportunity to bring more than 30,000 dedicated and talented employees together to lead the in-home healthcare industry’s transition to value-based reimbursement and highly coordinated care.”

William B. Yarmuth, Almost Family’s chairman and CEO, added, “In my opinion, we are combining two of America’s most successful home healthcare companies to create what will be the best-run, best-positioned in-home healthcare company in America.  The complementary nature of our two firms provides incredible fit, adding clinical, operational and financial strength, and depth without any meaningful conflicts or overlaps in management, geography, and service capabilities.  I believe the combined company will have the management team with the broadest and deepest experience of all the national in-home healthcare providers.

“By combining the best of both our long track records of success and patient-focused cultures, we will be able to accomplish much more together than either of us could possibly achieve alone.  I am extremely proud of the work we’ve done, the progress we’ve made, and the tremendous prospects for our future together. I look forward to working with Keith and the rest of the management team in the continued evolution of these companies.”

Jefferies LLC is serving as financial advisor to LHC Group and Alston & Bird LLP is serving as its legal advisor. Guggenheim Securities, LLC is serving as financial advisor to Almost Family and Gibson, Dunn & Crutcher LLP is serving as its legal advisor.

Conference Call
LHC Group and Almost Family will host a joint conference call today at 11:00 a.m. Eastern time to discuss the proposed merger. The toll-free number to call for this interactive teleconference is (866) 393‑1608 (international callers should call (973) 890-8327). A telephonic replay of the conference call will be available through midnight on November 23, 2017, by dialing (855) 859‑2056 (international callers should call (404) 537-3406) and entering confirmation number 1169538.

A live broadcast of the joint conference call as well as presentation materials will be available under the Investor tabs at www.LHCgroup.com and www.AlmostFamily.com.  A one-year online replay will be available approximately an hour following the conclusion of the live broadcast.

About LHC Group, Inc.
LHC Group, Inc. is a national provider of non-acute healthcare services, providing quality, cost-effective healthcare to patients primarily within the comfort and privacy of their home or place of residence. LHC Group provides a comprehensive array of healthcare services through home health, hospice, community‑based services agencies and facility-based services. LHC Group operates 320 home health services locations, 92 hospice locations, 12 community-based service locations and 15 long-term acute care hospitals (LTACHs).

About Almost Family, Inc.
Almost Family, Inc., founded in 1976, is a leading national provider of home healthcare services, with 332 branch locations in 26 states, including its joint venture with Community Health Systems, Inc.. Almost Family, Inc. and its subsidiaries operate home health, other home-based services and healthcare innovations segments.

Forward-Looking Statements
This press release contains “forward-looking statements” (as defined in the Securities Litigation Reform Act of 1995) regarding, among other things, future events or the future financial performance of LHC Group, Inc. (“LHC Group”) and Almost Family, Inc. (“Almost Family”). Words such as “anticipate,” “expect,” “project,” “intend,” “believe,” “will,” “estimates,” “may,” “could,” “should” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. The closing of the proposed transaction is subject to the approval of the stockholders of LHC Group and Almost Family, regulatory approvals and other customary closing conditions. There is no assurance that such conditions will be met or that the proposed transaction will be consummated within the expected time frame, or at all. Forward-looking statements relating to the proposed transaction include, but are not limited to: statements about the benefits of the proposed transaction, including anticipated earnings accretion, synergies and cost savings and future financial and operating results; LHC Group’s and Almost Family’s plans, objectives, expectations, projections and intentions; the expected timing of completion of the proposed transaction; and other statements relating to the transaction that are not historical facts. Forward-looking statements are based on information currently available to LHC Group and Almost Family and involve estimates, expectations and projections. Investors are cautioned that all such forward-looking statements are subject to risks and uncertainties, and important factors could cause actual events or results to differ materially from those indicated by such forward-looking statements. With respect to the proposed transaction, these risks, uncertainties and factors include, but are not limited to: the risk that LHC Group or Almost Family may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; the risk that required stockholder approvals may not be obtained; the risks that the other condition(s) to closing of the transaction may not be satisfied; the length of time necessary to consummate the proposed transaction, which may be longer than anticipated for various reasons; the risk that the businesses will not be integrated successfully; the risk that the cost savings, synergies and growth from the proposed transaction may not be fully realized or may take longer to realize than expected; the diversion of management time on transaction-related issues; the risk that costs associated with the integration of the businesses are higher than anticipated; and litigation risks related to the transaction. With respect to the businesses of LHC Group and/or Almost Family, including if the proposed transaction is consummated, these risks, uncertainties and factors include, but are not limited to: changes in, or failure to comply with, existing government regulations that impact LHC Group’s and/or Almost Family’s businesses; legislative proposals for healthcare reform; the impact of changes in future interpretations of fraud, anti-kickback, or other laws; changes in Medicare and Medicaid reimbursement levels; changes in laws and regulations with respect to Accountable Care Organizations; changes in the marketplace and regulatory environment for Health Risk Assessments; decrease in demand for LHC Group’s or Almost Family’s services; the potential impact of the announcement or consummation of the proposed transaction on relationships with customers, joint venture and other partners, competitors, management and other employees, including the loss of significant contracts or reduction in revenues associated with major payor sources; ability of customers to pay for services; risks related to any current or future litigation proceedings; potential audits and investigations by government and regulatory agencies, including the impact of any negative publicity or litigation; the ability to attract new customers and retain existing customers in the manner anticipated; the ability to hire and retain key personnel; the risk that the credit ratings of the combined company or its subsidiaries may be different from what the companies expect and/or risks related to the ability to obtain financing; increased competition from other entities offering similar services as offered by LHC Group and Almost Family; reliance on and integration of information technology systems; ability to protect intellectual property rights; impact of security breaches, cyber-attacks or fraudulent activity on LHC Group’s or Almost Family’s reputation; the risks associated with assumptions the parties make in connection with the parties’ critical accounting estimates and legal proceedings; the risks associated with the combined company’s expansion strategy, the successful integration of recent acquisitions, and if necessary, the ability to relocate or restructure current facilities; and the potential impact of an economic downturn or effects of tax assessments or tax positions taken, risks related to goodwill and other intangible asset impairment, tax adjustments, anticipated tax rates, benefit or retirement plan costs, or other regulatory compliance costs.

Additional information concerning other risk factors is also contained in LHC Group’s and Almost Family’s most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other Securities and Exchange Commission (“SEC”) filings.

Many of these risks, uncertainties and assumptions are beyond LHC Group’s or Almost Family’s ability to control or predict. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the information currently available to the parties on the date they are made, and neither LHC Group nor Almost Family undertakes any obligation to update publicly or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release. Neither LHC Group nor Almost Family gives any assurance (1) that either LHC Group or Almost Family will achieve its expectations, or (2) concerning any result or the timing thereof. All subsequent written and oral forward-looking statements concerning LHC group, Almost Family, the proposed transaction, the combined company or other matters and attributable to LHC Group or Almost Family or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above.

Additional Information And Where To Find It
The proposed transaction between LHC Group and Almost Family will be submitted to the respective stockholders of LHC Group and Almost Family for their consideration. LHC Group will file with the SEC a registration statement on Form S-4 that will include a joint proxy statement of LHC Group and Almost Family that also constitutes a prospectus of LHC Group. LHC Group and Almost Family will deliver the joint proxy statement/prospectus to their respective stockholders as required by applicable law. LHC Group and Almost Family also plan to file other documents with the SEC regarding the proposed transaction. This press release is not a substitute for any prospectus, proxy statement or any other document which LHC Group or Almost Family may file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF LHC GROUP AND ALMOST FAMILY ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT LHC GROUP, ALMOST FAMILY, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and stockholders will be able to obtain free copies of the joint proxy statement/prospectus and other documents containing important information about LHC Group and Almost Family, once such documents are filed with the SEC, through the website maintained by the SEC at www.sec.gov. LHC Group and Almost Family make available free of charge at www.lhcgroup.com and www.almostfamily.com, respectively (in the “Investor” or “Investor Relations” section, as applicable), copies of materials they file with, or furnish to, the SEC.

Participants In The Merger Solicitation
LHC Group, Almost Family, and certain of their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of LHC Group and Almost Family in connection with the proposed transaction. Information about the directors and executive officers of LHC Group is set forth in its proxy statement for its 2017 annual meeting of stockholders, which was filed with the SEC on April 28, 2017. Information about the directors and executive officers of Almost Family is set forth in its proxy statement for its 2017 annual meeting of shareholders, which was filed with the SEC on April 7, 2017. These documents can be obtained free of charge from the sources indicated above. Other information regarding those persons who are, under the rules of the SEC, participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available.

No Offer or Solicitation
This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed transaction between LHC Group and Almost Family or otherwise, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Non-GAAP Financial Information
This press release includes certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA and Adjusted Earnings per Share. The companies use these non-GAAP financial measures in operating its business because management believes they are less susceptible to variances in actual operating performance that can result from the excluded items. The companies present these financial measures to investors because they believe they are useful to investors in evaluating the primary factors that drive the companies’ operating performance. The items excluded from these non-GAAP measures are important in understanding LHC Group’s and Almost Family’s financial performance, and any non-GAAP measures presented should not be considered in isolation of, or as an alternative to, GAAP financial measures. Since these non-GAAP financial measures are not measures determined in accordance with GAAP, have no standardized meaning prescribed by GAAP and are susceptible to varying calculations, these measures, as presented, may not be comparable to other similarly titled measures of other companies. Adjusted EBITDA of LHC Group and Almost Family is defined as net income (loss) before income tax benefit (expense), interest expense, depreciation and amortization expense, and transaction costs related to previous transactions. Adjusted Earnings per Share is defined as diluted earnings per share adjusted transaction costs related to acquisition activities, net of estimated tax benefit.

Contact:
Investors:
LHC Group
Eric Elliott
Senior Vice President of Finance
(337) 233-1307
eric.elliott@lhcgroup.com

Almost Family
Steven Guenthner
President and Principal Financial Officer
(502) 891-1000
steveguenthner@almostfamily.com

Media:
Schmidt Public Affairs
Rebecca Reid
(410) 212-3843
rreid@schmidtpa.com

Thursday, November 16th, 2017 Uncategorized Comments Off on $AFAM & $LHCG In-Home Healthcare Services Merger of Equals

$ABIO European Patent for Genetic-Targeting NCE in Cardiovascular Diseases

ARCA Plans Genetically-Targeted Development of a New Chemical Entity (AB171) for Peripheral Arterial Disease and Heart Failure

WESTMINSTER, Colo., Nov. 16, 2017 — ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the European Patent Office’s issuance of a patent (EPO # 2515899) on methods of treating cardiovascular disease and conditions with a thiol-substituted isosorbide mononitrate based on genetic targeting.  The European patent, entitled “Methods and Compositions for Cardiovascular Diseases and Conditions,” provides protection for this novel approach to treating patients with cardiovascular disease and conditions.  The European patent has been validated in ten countries: Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland and the United Kingdom.  ARCA has related patent applications pending in the United States Patent Office and Canadian Intellectual Property Office.

ARCA has discovered what it believes to be a pharmacogenetic target for AB171 that is the basis for the patents and which the company believes may enable genetically-targeted cardiovascular development programs.  ARCA plans to advance development of AB171, a potential New Chemical Entity (NCE), for the treatment of two cardiovascular indications: peripheral arterial disease (PAD) and chronic heart failure (HF).  The compound, formerly known as LA-419, was previously under development at Lacer, S.A., where multiple Phase 1 studies were conducted to assess pharmacokinetics and clinical tolerability.  ARCA has collaborated with Elucida Research in the preclinical development of AB171.  The Company anticipates initiating chemistry, manufacturing and controls (CMC) activities in the first half of 2018, followed by nonclinical studies with AB171 to support submission of an Investigational New Drug (IND) Application.

“ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to functionally important genetic variants in drug targets that also serve as biomarkers, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. The addition of AB171 to our genetically-targeted development pipeline, including the Gencaro atrial fibrillation-heart failure program, is consistent with that mission,” commented Dr. Michael Bristow, ARCA’s President and CEO.  “We believe our experience with GENETIC-AF has established the feasibility of in-house design and execution of pharmacogenetic clinical trials, and has provided invaluable insights into this type of drug development.  We are eagerly anticipating the top line results of the Phase 2B GENETIC-AF trial, expected in the latter part of the first quarter of 2018, which following discussions with FDA, may inform further development of Gencaro. ARCA’s current levels of staffing and expertise allow for the simultaneous activation of the AB171 program and organization of the potential next steps for Gencaro.”

ARCA believes that its current cash, cash equivalents and marketable securities will be sufficient to fund its operations, at its projected cost structure, through the end of second quarter of 2018.

About AB171

AB171 is a thiol-containing derivative of isosorbide mononitrate.  Pre-clinical data indicate that AB171 has significant anti-oxidant properties and is favorably differentiated from other nitrates for prevention of myocardial remodeling, anti-atherosclerotic effects and the development of tolerance. ARCA believes the unique pharmacology of AB171, coupled with targeting to genetically-identified enhanced response subpopulations, has the potential to translate to better long-term responses than treatment with traditional pharmacotherapy.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases through a precision medicine approach to drug development.  ARCA’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of patients with atrial fibrillation and HF with reduced ejection fraction.  ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment.  ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. The Gencaro development program has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).  ARCA plans to develop AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically-targeted treatment for PAD and for HF.  For more information, please visit www.arcabio.com.

Safe Harbor Statement

This press release contains “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to, statements regarding, the anticipated characteristics of AB171 as a potential genetically-targeted treatment for PAD and for HF, the potential timeline for development of AB171, including any IND submission related thereto, the potential for genetic variations to predict individual patient response to Gencaro or AB171, Gencaro’s potential to treat AF, and the potential for Gencaro to be the first genetically-targeted AF prevention treatment.  Such statements are based on management’s current expectations and involve risks and uncertainties.  Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA’s financial resources and whether they will be sufficient to meet its business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes.  These and other factors are identified and described in more detail in ARCA’s filings with the Securities and Exchange Commission, including without limitation ARCA’s annual report on Form 10-K for the year ended December 31, 2016, and subsequent filings.  ARCA disclaims any intent or obligation to update these forward-looking statements.

Investor & Media Contact:
Derek Cole
720.940.2163
derek.cole@arcabio.com

Thursday, November 16th, 2017 Uncategorized Comments Off on $ABIO European Patent for Genetic-Targeting NCE in Cardiovascular Diseases

$ICON Receives Letter from NASDAQ

NEW YORK, Nov. 16, 2017  — Iconix Brand Group, Inc. (NASDAQ: ICON)  (the “Company”), announced today that as a result of the previously disclosed delayed filing of its Form 10-Q for the period ended September 30, 2017 (the “3Q Form 10-Q”), it has received a customary deficiency notice from the NASDAQ Listing Qualifications Staff.  The delayed filing is a result of additional time required for the Company to complete impairment testing of its goodwill and intangible assets in order to determine the amount of any non-cash intangible asset impairment charge on any of its brands, which the Company will reflect in its financial statements.

The NASDAQ letter states that the Company is not currently in compliance with NASDAQ Listing Rule 5250(c)(1). The letter requests that the Company submit a plan to regain compliance with respect to the NASDAQ’s continued listing standards no later than January 16, 2018. If the Company fails to provide a timely plan or the NASDAQ staff determines the Company’s plan is insufficient to regain compliance, the Company may be subject to delisting from the NASDAQ Stock Market. However, the Company anticipates that it will file the 3Q Form 10-Q by January 16, 2018, and believes that submission of a plan will not be necessary.

Cautionary Statement

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. We caution you that the forward-looking information presented in this press release is not a guarantee of future events, and that actual events and results may differ materially from those made in or suggested by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “plan,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe” or “continue” or the negative thereof or variations thereon or similar terminology. A number of important factors could cause actual events and results to differ materially from those contained in or implied by the forward-looking statements, including how promptly we are able to complete impairment testing of our goodwill and intangible assets, as well as those factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2016, subsequent Quarterly Reports on Form 10-Q and subsequent Current Reports on Form 8-K filed with the SEC, which can be found at the SEC’s website www.sec.gov, each of which is specifically incorporated into this press release. Any forward-looking information presented herein is made only as of the date of this press release, and we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.

Contact Information:

Jaime Sheinheit
VP, Investor Relations
Iconix Brand Group, Inc.
jsheinheit@iconixbrand.com
212.819.2096

Thursday, November 16th, 2017 Uncategorized Comments Off on $ICON Receives Letter from NASDAQ

$MRTX Announces Pricing Of Public Offering Of Common Stock

SAN DIEGO, Nov. 16, 2017 — Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 2,015,901 shares of its common stock at a price to the public of $13.00 per share. In addition, and in lieu of common stock, Mirati is offering to certain investors pre-funded warrants to purchase up to an aggregate of 4,137,999 shares of common stock at a purchase price of $12.999 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds from this offering are expected to be approximately $80.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. The offering is expected to close on or about November 20, 2017, subject to customary closing conditions. Mirati has granted the underwriters a 30-day option to purchase up to an additional 923,085 shares of common stock in connection with the public offering. All of the securities are being offered by Mirati.

Mirati expects to use the net proceeds from this offering for general corporate purposes, including for clinical development of sitravatinib and mocetinostat, for the preclinical and clinical development of its KRAS inhibitor, for the development of other preclinical programs, and working capital.

Cowen and Barclays are acting as joint book-running managers in the offering. SunTrust Robinson Humphrey, Oppenheimer & Co. and H.C. Wainwright & Co. are acting as co-lead managers in the offering.

The securities described above are being offered by Mirati pursuant to a shelf registration statement filed by Mirati with the Securities and Exchange Commission (“SEC”) that was declared effective on November 18, 2015. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from the offices of Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806; or from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (888) 603-5847, or by email at Barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Mirati Therapeutics

Mirati Therapeutics is a clinical-stage biotechnology company focused on developing a pipeline of targeted oncology products intended to treat specific genetic and epigenetic drivers of cancer. This approach is transforming the treatment of patients by targeting the genetic changes in tumor cells that result in uncontrolled tumor growth and migration. Mirati’s precision oncology programs seek to treat the patients most likely to benefit from targeted oncology treatments and are driven by drugs that target very specific genetic mutations, directed by genomic tests that identify patients who carry those driver mutations. Mirati’s immuno-oncology programs are novel small molecule drugs designed to enhance and expand the efficacy of checkpoint inhibitors when given in combination. In addition to its clinical programs, Mirati has active discovery research efforts focused on novel oncology targets. The promise of these approaches includes potentially better patient outcomes, more efficient cancer treatment and faster drug development.

Forward-Looking Statements

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking information and forward-looking statements (collectively “forward-looking statements” within the meaning of applicable securities laws). Such statements, based as they are on the current expectations of management of Mirati and upon what management believes to be reasonable assumptions based on information currently available to it, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Mirati’s control. Such statements can usually be identified by the use of words such as “may,” “would,” “believe,” “intend,” “plan,” “anticipate,” or “estimate” and other similar terminology, or state that certain actions, events or results “may” or “would” be taken, occur or be achieved. Forward-looking statements in this release include, but are not limited to, statements related to the expected completion, timing and size of the public offering of common stock and Mirati’s expected used of the proceeds from the offering.

Whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, assumptions and uncertainties, many of which are beyond our control, and the effects of which can be difficult to predict. These risks include those associated with market risks and uncertainties and the satisfaction of customary closing conditions for an offering of securities, as well as those inherent in drug development, whether Mirati will be able to obtain financing when needed or on favorable terms, and other risks described in Mirati’s filings with the SEC. In evaluating any forward-looking statements in this release, Mirati cautions readers not to place undue reliance on any forward-looking statements. Unless otherwise required by applicable securities laws, Mirati does not intend, nor does it undertake any obligation, to update or revise any forward-looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise.

Thursday, November 16th, 2017 Uncategorized Comments Off on $MRTX Announces Pricing Of Public Offering Of Common Stock

$EGLT Positive Top-Line Results Phase 3 Safety on Egalet-002

WAYNE, Pa., Nov. 16, 2017 — Egalet Corporation (Nasdaq: EGLT) (Egalet), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced positive top-line results from a phase 3 study evaluating the safety of Egalet-002, an abuse-deterrent, extended-release oxycodone developed using a unique application of the Guardian™ Technology.

Egalet-002 was generally well-tolerated and the incidence of adverse events reported was generally consistent with outcomes expected following treatment with an extended-release oxycodone formulation.

“We believe the positive phase 3 safety study result validates this unique application of our Guardian Technology which was used to develop our abuse-deterrent, extended-release oxycodone, Egalet-002,” said Bob Radie, president and chief executive officer of Egalet. “Given the ongoing issues of chronic pain and prescription abuse, we continue to believe there is a need for products like Egalet-002.”

The objective of the open-label phase 3 study was to evaluate the safety and tolerability of Egalet-002 for up to 56 weeks in opioid-experienced patients with moderate-to-severe chronic noncancer pain. The goal of the study was to administer Egalet-002 to approximately 150 patients for six months and at least 50 patients for one year. The study enrolled 281 patients at 39 clinicals site in the United States who had a history of moderate-to-severe chronic non-cancer pain for six months or more.

In addition, a phase 3 trial evaluating the safety and efficacy of Egalet-002 in patients with moderate-to-severe chronic pain is expected to be completed by year end.

Guardian™ Technology
Egalet’s Guardian Technology has many applications and has been used to develop abuse-deterrent forms of commonly abused prescription medications. Egalet’s proprietary Guardian Technology is a polymer matrix tablet technology that utilizes a novel application of the well characterized manufacturing process of injection molding, which results in tablets that are hard and difficult to manipulate for misuse and abuse. This approach offers the ability to design tablets with controlled-release profiles as well as physical and chemical properties that have been demonstrated to resist both common and rigorous methods of manipulation. Tablets manufactured with Guardian Technology have been shown to have increased resistance to physical methods of manipulation, such as cutting, crushing, grinding or breaking, using a variety of mechanical and electrical tools. They are also resistant to chemical manipulation and attempts at extraction and turn into a viscous hydrogel on contact with liquid, making syringeability very difficult.

About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO® ER (morphine sulfate) extended-release tablets for oral use —CII, developed using Egalet’s proprietary Guardian™ Technology, OXAYDO® (oxycodone HCI, USP) tablets for oral use only —CII and SPRIX® (ketorolac tromethamine) Nasal Spray. Using Guardian Technology, Egalet is developing a pipeline of clinical-stage, product candidates for which we are seeking partners including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For full prescribing information on ARYMO ER, including the boxed warning and medication guide, please visit arymoer.com. For full prescribing information on SPRIX, including the boxed warning and medication guide, please visit sprix.com. For full prescribing information on OXAYDO, including the boxed warning and medication guide, please visit oxaydo.com.

Safe Harbor
Statements included in this press release that are not historical in nature and contain the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “look forward to” and other similar expressions are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the successful implementation and realization of the anticipated benefits from Egalet’s expense reduction plan; Egalet’s estimates with regard to its operating plan, expenses, future revenues, capital requirements and needs for additional financing; the success of Egalet’s clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; Egalet’s ability to obtain and maintain regulatory approval of its product candidates and the labeling claims that Egalet believes are necessary or desirable for successful commercialization of its products and product candidates; Egalet’s ability to maintain the intellectual property position of its products and product candidates; Egalet’s ability to identify and reliance upon qualified third parties to manufacture its products; Egalet’s ability to commercialize its products, and to do so successfully; the costs of commercialization activities, including marketing, sales and distribution; Egalet’s ability to execute on its sales and marketing strategy, including developing relationships with customers, physicians, payors and other constituencies; the size and growth potential of the markets for Egalet’s products and product candidates, and Egalet’s ability to service those markets; Egalet’s ability to obtain reimbursement and third-party payor contracts for its products; Egalet’s ability to service or refinance its debt obligations; Egalet’s ability to raise additional funds to execute its business plan and growth strategy on terms acceptable to Egalet, if at all; Egalet’s ability to find and hire qualified sales professionals; the rate and degree of receptivity in the marketplace and among physicians to Egalet’s products; the success of products which compete with Egalet’s that are or become available; general market conditions; and the Risk Factors set forth in Egalet’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the United States Securities and Exchange Commission (SEC) and in other filings Egalet makes with the SEC from time to time.  In addition, the forward-looking statements included in this press release represent Egalet’s views only as of the date hereof. Egalet anticipates that subsequent events and developments may cause its views to change. While Egalet may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: ir@egalet.com
Tel: 484-259-7370

Thursday, November 16th, 2017 Uncategorized Comments Off on $EGLT Positive Top-Line Results Phase 3 Safety on Egalet-002

$CIIX UPDATE: ChineseHempOil.com OptHemp Launch on Amazon for Singles Day 2017

SAN GABRIEL, California, November 16, 2017 —

ChineseInvestors.com, Inc. (OTCQB: CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announced that its wholly owned subsidiary, ChineseHempOil.com, Inc., launched its OptHemp product line on Amazon.com kicking off a multi-channel campaign geared to both the US and Chinese-American markets during the 9th annual Singles Day Celebration.

This commences the e-commerce marketplace initiative that the Company set into motion in early June through a strategic partnership with a top 100 platinum level partner seller on Amazon Marketplace that has agreed to include the OptHemp product line in its limited catalog for resale through the Amazon Channel. This partnership brings to the OptHemp product line, the full weight and power of a national sales and marketing agency that specializes in providing business solutions including headquarter sales services, analytics, insights and intelligence, retail services, marketing, digital technology and business process outsourcing. The OptHemp products launched on Amazon.com represent the Company’s first use of Amazon for product sales.

“We are excited about the Amazon launch for Singles Day, 11/11/2017. Guanggun Jie which translated literally means ‘Single Sticks’ Holiday’ is an entertaining festival widespread among young Mainland Chinese people, to celebrate being single. This festival has become one the largest offline and online shopping days in the world, and as it has morphed into a global shopping holiday in the last several years; therefore, we thought it was the perfect day to launch with Amazon.com in advance of the holidays,” said Warren Wang, CEO of ChineseInvestors.com, Inc.

The Company also has plans to launch two new, first-of-their-kind products that will be available on Amazon.com before the Black Friday and Cyber Monday shopping extravaganzas. With two product lines launching on Amazon.com, the Company hopes to make the most of the upcoming holiday buying season positioning itself to earn generous revenues.

The entire OptHemp line can be viewed on Amazon.com at:

https://www.amazon.com/dp/B076T9452S

https://www.amazon.com/dp/B076TQHTPJ

https://www.amazon.com/dp/B076TJZQJV

https://www.amazon.com/dp/B077BQ44YK

https://www.amazon.com/dp/B077BPFD21

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products.

For more information, visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom;

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1-214-636-2548

Corporate Communications:
NetworkNewsWire (NNW)
+1-212-418-1217
Editor@NetworkNewsWire.com

http://www.NetworkNewsWire.com

Thursday, November 16th, 2017 Uncategorized Comments Off on $CIIX UPDATE: ChineseHempOil.com OptHemp Launch on Amazon for Singles Day 2017

$SGH Showcases its Gen-Z NVRAM Media Controller Card at Super Computing 2017

NEWARK, Calif., Nov. 15, 2017  —
Who:

SMART Modular Technologies, a subsidiary of SMART Global Holdings, Inc., (NASDAQ:SGH), and a leader in specialty memory, storage and hybrid solutions including memory modules, Flash memory cards and other solid state storage products.

What:       
SMART is showcasing its new Gen-Z NVRAM Media Controller Card in a PCIe HHHL (half-height half-length) form factor. SMART is supporting OEMs adopting the new Gen-Z high bandwidth, low latency interconnect protocol standard for handling big data. The protocol was developed to enable new solution architectures to deliver high levels of performance (high-bandwidth, low-latency), software efficiency, power optimizations, and industry agility. It operates at data rates up to 64Gb/s on two separate interfaces with less than 100ns load-to-use memory latency and incorporates 768GB of Flash and 16GB of DRAM. SMART’s card showcases how the Gen-Z standard is designed to handle advance workloads, enabling data centric computing with scalable memory pools and resources for real-time analytics and in-memory applications. OEMs with plans to launch Gen-Z-enabled high-performance computing systems can use SMART’s media storage controller card as a storage device in Gen-Z fabrics.

When:
November 14-16, 2017

Where:
Super Computing 2017, Colorado Conference Center, Denver, CO.  SMART will be showcasing its Gen-Z NVRAM Media Controller Card in a static display in Booth #273. A live demonstration can also be seen in the Gen-Z Consortium Booth #992

To learn more about SMART’s Gen-Z NVRAM Media Controller Card please visit www.smartm.com/gen-z.

Connect with SMART on LinkedIn at http://www.linkedin.com/company/smart-modular-technologies

About SMART Modular Technologies
SMART Modular Technologies is a global leader in specialty memory, storage and hybrid solutions serving the electronics industry for over 25 years. SMART Modular delivers solutions to a broad customer base, including OEMs in computing, networking, communications, storage, mobile and industrial markets. Focused on providing extensive customer-specific design capabilities, technical support and value-added testing services, SMART collaborates closely with their global OEM customers throughout their design process and across multiple projects to create memory, storage and hybrid solutions for demanding applications with differentiated requirements. Taking innovations from the design stage through manufacturing and supply, SMART Modular has developed a comprehensive product line comprised of DRAM, Flash and hybrid memory technologies across various form factors. SMART Modular is a subsidiary of SMART Global Holdings, Inc. See www.smartm.com for more information.

Contact:
Arthur Sainio
SMART Modular Technologies
(510) 624-8126
arthur.sainio@smartm.com

Wednesday, November 15th, 2017 Uncategorized Comments Off on $SGH Showcases its Gen-Z NVRAM Media Controller Card at Super Computing 2017

$EMMBF Completes Bought Deal Financing

November 15, 2017

NetworkNewsWire Editorial Coverage: Licensed cannabis producers in Canada are growing at remarkable pace, swept forward by the country’s legalization of medicinal marijuana in 2001 and impending legalization for recreational use of the plant, set for July 1, 2018. Amid demand for cannabis in various forms, oils are a significant contributor to the growth of leading producers that are keeping an eye on evolving market trends (http://nnw.fm/Xa32z). Key industry players such as ABcann Global Corp. (OTCQB: ABCCF) (TSX.V: ABCN) (ABCCF Profile), Emblem Cannabis, Inc. (OTC: EMMBF) (TSXV: EMC), Emerald Health Therapeutics, Inc. (OTCQX: EMHTF) (EMH: CC), OrganiGram Holdings, Inc. (OTC: OGRMF) (CVE: OGI) and Supreme Pharmaceuticals, Inc. (OTC: SPRWF) (TSXV: FIRE) are leading the industry and adjusting their strategies to include mounting consumer demand for oils.

ABcann Global (OTCQB: ABCCF) (TSX.V: ABCN) is leveraging its position as a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis to expand its product line to include cannabis oils. As one of Canada’s first licensed cannabis producers, ABcann is significantly ahead of the curve when it comes to production capacities. The company’s licensed and fully operational Vanluven Facility produces 1,000 kg annually. Construction on the company’s Kimmett facility, an industry-leading, purpose-built, world class style facility, is under contract with another 65 acres under full Abcann ownership for future expansion plans. As noted in its corporate presentation (http://nnw.fm/W6rbx), ABcann’s yield per square foot is 100 percent over the industry average.

Pivoting off its deep roots in pharmaceutical-grade cannabis, ABcann’s wholly owned ABcann Medicinals, Inc. subsidiary in August launched CBD-Med, one of Canada’s highest legal CBD:THC (cannabidol:tetrahydrocannabinol) ratio products available on the market (http://nnw.fm/sYv7g), under Health Canada regulations.

The launch of CBD-Med is on par with ABcann’s broader strategy to diversify its product line and capture its share of demand for cannabis oils. Products that ABcann will have available for patients are expected to include a 1-1 THC/CBD drop, a high THC dropper and a high CBD dropper.

“The development of these products is in line with ABcann’s corporate strategy as a premium product provider of organic, pesticide free cannabis,” ABcann’s executive chairman stated in the press release. “As the Company continues to scale production capacity, our product line will expand as we strive to increase shareholder value through capturing a larger market share of the current global medical markets.”

CBD-Med’s high CBD content is a vital differentiating factor. Although the virtues of THC have been loudly sung, many patients exhibit adverse reactions, such as short-term memory impairment, dysphoria (feeling uneasy for no apparent reason), increased levels of anxiety and even panic attacks to the cannabinoid. On the other hand, CBD is devoid of such side effects and, moreover, appears to mitigate the injurious effects of THC when taken in conjunction with it.

More than half (54%) the cannabis strains on the Canadian market have a high THC-CBD ratio, with THC over 15% and CBD less than 1%. Many others (29%) have less THC but negligible amounts of CBD, with THC less than 15% and CBD below 1%. Only 14% of strains have both THC and CBD levels that exceed 5%. And just 3% of strains have less than 1% THC and more than 9% CBD, a highly prized category in which CBD-Med can be found.

Emblem Cannabis, Inc. (OTC: EMMBF) (TSXV: EMC) is also strategizing for its share of the market. Earlier this month the company was granted a license to sell cannabis oils (http://nnw.fm/0rdcB). Late last year, Emblem was granted a supplemental license for the production of cannabis extracts. John Stewart, President of Emblem’s Pharmaceutical Division has emphasized the importance of this license to the company’s plan to provide high quality, differentiated cannabis products, in a variety of formats. Emblem plans to offer a selection of cannabis oils, including those from CBD dominant strains, THC dominant strains and strains with both CBD and THC content. The company believes cannabis oils and related formulations provide a level of consistency and dosage accuracy that cannot be achieved with dried flower. Such products also provide a method of consumption that many consumers find to be substantially more precise and convenient.

Meanwhile, Emerald Health Therapeutics, Inc. (OTCQX: EMHTF) (EMH: CC), through its Emerald Health Botanicals subsidiary, as a licensed producer is already offering eight oils with varying levels of THC, THCA, CBD, and THC to CBD ratios. The product line includes the company’s recently launched CBD-25 and CBD-50 medical cannabis oils containing approximately 25 milligrams and 50 mg of CBD per milliliter (http://nnw.fm/mSfc3). The company believes that CBD-50 will provide a unique treatment option to doctors and patients seeking high CBD potency with minimal THC. Its management is of the opinion that CBD-50 contains the highest amount of CBD per milliliter on the ACMPR market today. Emerald Health Botanicals is now licensed to produce and sell both dried medical cannabis flower and medical cannabis oil in Canada. The subsidiary currently operates an indoor facility in Victoria, BC, and is making progress on expansion plans for a 32-acre property in Metro Vancouver and a joint venture with Village Farms that utilizes a 25-acre existing greenhouse complex in Delta, BC.

Moncton, New Brunswick-based OrganiGram Holdings, Inc. (OTC: OGRMF) (CVE: OGI) in June received an upgrade to its licensed producer status (http://nnw.fm/47QlM), allowing both the production and sale of cannabis oil extracts, as well as the company’s current dried medical cannabis products. Quickly acting on that approval, OrganiGram released Shubie, a pure CBD edible oil that expands its range of cannabis oil offerings. Shubie is an ethanol-extracted cannabis oil formulated in an organic sunflower oil base (http://nnw.fm/RTd4Y). This 50ml formulation boasts 23.7 mg/ml CBD and 1.39 mg/ml THC. Like the other oils in the OrganiGram line up, Shubie was named for an iconic Atlantic Canadian waterway, the Shubenacadie River.

Supreme Pharmaceuticals’ (OTC: SPRWF) (TSXV: FIRE) wholly owned 7ACRES subsidiary recently received approval from Health Canada to begin cultivation at its 30,000 square-foot flowering rooms at the company’s hybrid grow facility. The additional flowering rooms increases the size of 7ACRES’ flowering facility to 40,000 square feet. 7ACRES, and thus Supreme, also has its footing in oils via a retail partnership with Aurora Cannabis (TSX: ACB) (OTC: ACBFF). In its fourth-quarter financial results, Aurora said sales of dried medical cannabis and cannabis oils contributed $5.6 million to revenues, of which $0.4 million (7.1%) was generated in Germany and $5.2 million in Canada (http://nnw.fm/MOgY2).

Adoption of cannabis oil continues to increase as a preferred alternative to cannabinoid consumption, providing cannabis cultivators with an unprecedented market opportunity paced by rising consumer demand.

For more information on ABcann Global please visit: ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Wednesday, November 15th, 2017 Uncategorized Comments Off on $EMMBF Completes Bought Deal Financing

$VERI Makes AI Accessible and Actionable with AWS Marketplace Listing

COSTA MESA, Calif.

Listing Brings Orchestrated, Multi-Engine Artificial Intelligence to AWS Customers

Veritone®, Inc. (NASDAQ: VERI), a leading provider of artificial intelligence (AI) insights and cognitive solutions, today announced the immediate availability of its aiWARE™ platform on AWS Marketplace. As an Advanced Technology Partner in the AWS Partner Network (APN), Veritone provides AWS customers with full access to aiWARE, enabling the index and search of unstructured data to derive actionable business insights.

“Institutions and organizations recognize the necessity of analyzing unstructured data at scale in near real-time,” said Chad Steelberg, chairman and chief executive officer of Veritone. “aiWARE provides them a way to unlock this data, accessing deep analytics and providing business insights like never before. Our collaboration with Amazon Web Services allows customers to deploy our platform in the cloud within minutes, giving them the ability to harness AI to make decisions with more confidence.”

The current landscape of artificial intelligence solutions can be expensive, skill-intensive, and difficult to implement. Such solutions also tend to be siloed, extremely narrow in their application, and challenged in their ability to deliver real value. As a result, the power of AI is largely inaccessible to most organizations.

Veritone makes AI accessible and actionable by combining more than 120 best-of-breed cognitive engines across major cognitive functions with a suite of powerful applications and a proprietary orchestration layer informed by machine learning. aiWARE produces time-correlated, multi-dimensional metadata from audio and video data, unlocking new insights from linear files.

“CBS RADIO delivers best-in-class experiences on-air, online and at live events and experiences for our audiences and advertising partners alike,” said Bob Philips, chief revenue officer, CBS RADIO. “Using Veritone aiWARE on AWS has armed us to more accurately measure across these platforms and deliver proven results – allowing for more data-driven, value-added discussions with our clients.”

Veritone will participate in AWS re:Invent on November 27 through December 1, 2017 at booth 2836.

About Veritone

Veritone (NASDAQ: VERI) is a leading artificial intelligence company that has developed a unique platform, aiWARE, which unlocks the power of AI-based cognitive computing to transform and analyze unstructured public and private audio and video data for clients in a variety of markets, including media, politics, legal and government. The open platform integrates an ecosystem of best-of-breed cognitive engines and powerful applications, which can be orchestrated together to reveal valuable, multivariate insights. aiWARE delivers unprecedented insights by unlocking data from linear files such as radio and TV broadcasts, surveillance footage and public and private content globally. To learn more about Veritone, please visit Veritone.com.

Safe Harbor Statement

This news release contains forward-looking statements, including without limitation statements regarding Veritone’s listing on the AWS Marketplace, its status as an Advanced Technology Partner in the AWS Partner Network, the use of the Veritone aiWARE platform by users and the expected benefits. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Assumptions relating to the foregoing involve judgments and risks with respect to various matters which are difficult or impossible to predict accurately and many of which are beyond the control of Veritone. Certain of such judgments and risks are discussed in Veritone’s SEC filings. Although Veritone believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized. In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by Veritone or any other person that their objectives or plans will be achieved. Veritone undertakes no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

BLASTmedia for Veritone, Inc.
Meghan Matheny, 317-806-1900 x115
meghan_matheny@blastmedia.com

Tuesday, November 14th, 2017 Uncategorized Comments Off on $VERI Makes AI Accessible and Actionable with AWS Marketplace Listing

$STLHF Appoints Craig Brown P.Eng. to Scientific Advisory Council

VANCOUVER, British Columbia , Nov. 14, 2017 — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLL) (OTCQX:STLHF) (FRA:S5L) is pleased to announce the appointment of Mr. Craig J. Brown, P. Eng., to the Company’s Scientific Advisory Council (SAC), effective immediately.

Mr. Brown is a widely respected hydrometallurgical expert with over 45 years experience in developing processes for separating a wide range of chemicals from aqueous solutions.  He was a central figure in the development and application of ion exchange technology, which is now well established and utilized in over 50 countries in dozens of different applications.  He has published hundreds of technical papers, has been awarded numerous patents and maintains a vast network of contacts at numerous major international research and development institutions including industrial, university and government organizations.  In addition to his technical expertise, Mr. Brown has extensive business experience, having held several corporate executive positions during his career.  Mr. Brown received his Bachelor of Applied Science in Chemical Engineering from the University of Toronto, and is a member of the Canadian Institute of Mining and Metallurgy and the International Committee of Ion Exchange.

Dr. Andy Robinson, President and COO of Standard Lithium, commented, “We are delighted to welcome Craig Brown as a new member of Standard Lithium’s Scientific Advisory Council.  Craig brings extensive and well-respected expertise in selective ion-exchange and hydrometallurgical technologies, and will be instrumental in developing modern process flowsheets as the Company continues its test work on lithium brines sourced from the Company’s projects in the Bristol Dry Lake basin in the Mojave Desert of California and the Smackover Formation of Arkansas.

Additionally, the Company is pleased to announce that it has begun the first phase of test work on a new lithium-selective Ion Exchange (“IX”) resin that has been in development for several years by one of the world’s largest suppliers of Li-specific IX resins.  This test-work expands and supplements the Company’s current testing program, and is an example of Standard Lithium’s data-driven approach to developing optimal process solutions for its suite of lithium brine projects.

About Standard Lithium Ltd.

Standard’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills.  The Company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities.  The Company is also commencing resource evaluation on 33,000 acres of brine leases located in the Smackover Formation.

Standard Lithium is listed on the TSX Venture under the trading symbol “SLL”; quoted on the OTCQX under the symbol “STLHF”; and on the Frankfurt Stock Exchange under the symbol “S5L”. Please visit the Company’s website at www.standardlithium.com.

On behalf of the Board,

Standard Lithium Ltd.

Robert Mintak, CEO & Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information.  These forward-looking statements or information may relate to future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information.  Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties.  Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements.  The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.

For further information, contact Anthony Alvaro at (604) 240 4793
Tuesday, November 14th, 2017 Uncategorized Comments Off on $STLHF Appoints Craig Brown P.Eng. to Scientific Advisory Council

$EMMBF Canadian Licensed Producers Prepare for Recreational Cannabis Legalization

November 14, 2017

NetworkNewsWire Editorial Coverage: A momentous cultural and economic change is soon coming to Canada, as the Canadian Government has committed to legalizing recreational marijuana on July 1, 2018. Already busy with demand for medicinal marijuana – which has been legal in Canada since 2001 – licensed cultivators are ramping up their production capabilities in anticipation of a staggering surge in demand. Investors are also taking notice, in October driving average gains of 7.6% among Canadian cannabis producers (http://nnw.fm/KJ29n). The Canadian Government is also making preparations for the impending legalization, emphasizing cannabis education and awareness for the nation’s youth (http://nnw.fm/b4U9O). This focus on health and safety adds weight to the proprietary, organic and pesticide-free growing systems of ABcann Global Corp. (OTCQB: ABCCF) (TSX.V: ABCN) (ABCCF Profile), which, thanks to a hefty investment by Cannabis Wheaton Income Corp. (OTCQB: CBWTF) (TSX.V: CBW), has the capital needed to increase its supply. Other licensed producers gearing up to meet demand Maricann Group, Inc. (OTCQB: MRRCF) (MARI: CC), Emblem Corp. (OTC: EMMBF) (EMC: CC) and MedReleaf Corp. (OTC: MEDFF) (LEAF: CC).

The impending legalization of marijuana for recreational use in Canada could offer licensed producers a chance to record tremendous growth in the coming months. According to a 2016 report by Deloitte, the legal Canadian marijuana market could soon be worth $18 billion annually. As for volume, Deloitte forecast annual demand for the plant at about 1.32 million pounds per year.

With a highly regulated system and strict licensing requirements, the Canadian market is a safe haven for investors looking to invest in quality products and companies in a market brimming with potential. However, an overly strict licensing process restricts supply, as seen in the U.S. State of Nevada (http://nnw.fm/He1F0).

As a result, the Canadian government has relaxed its licensing approval process, and established growers such as ABcann Global Corp. (OTCQB: ABCCF) (TSX.V: ABCN) have a head start. Focused on producing premium quality organic standardized medicinal cannabis, ABcann has developed a proprietary computerized system to control marijuana growing, which enables it to replicate the cultivation environment of any geographical location in the world. This level of control guarantees a consistent product of superior quality that is repeatable from batch to batch, something that is demanded by both physicians and patients. The company’s innovative system uses controlled lighting, organic fertilizers and soil media to deliver natural, safe products at high yields. Through strict environmental control of temperature, humidity and water, ABcann is able to eliminate the need for pesticides, which can taint supply.

Cultivation requires capital, and with $40 million in the bank, ABcann is especially well-positioned to increase its production capabilities. A hefty portion of this cash is from a $30 million with Cannabis Wheaton (OTCQB: CBWTF) (TSX.V: CBW) to fund the construction of additional ABcann production facilities.

ABcann currently operates a licensed 14,500-square-foot Vanluven facility located in Napanee, Ontario, and the company is gearing up to break ground on its new 150,000-square-foot Kimmet facility in Napanee. Even with the new facility, ABcann has plenty of wiggle room, as it also owns 65 acres of land for future development with full infrastructure already in place, which will be able to accommodate another growing facility estimated at 1.2 million square feet.

Experienced leadership is part of what has helped ABcann earn its stripes in the marijuana industry. At the helm of ABcann’s expansion strategies is a strong management team led by Barry Fishman, former CEO of Teva Canada, a producer of generics and specialty pharmaceuticals generating $1 billion in revenue. Fishman has a proven track record as CEO of three international companies where he exhibited his exceptional abilities in deal-making, mergers and acquisitions, and raising capital.

Fishman’s experience in international markets bodes well for ABcann’s pursuit of achieving greater market share in Canada, along with growth opportunities in Germany and other parts of Western Europe, as well as in South America.

Though ABcann’s current market valuation is USD$80 million (CAD$100.6+ million), the company’s capabilities place it among the ranks of larger cultivators like Maricann Group (OTCQB: MRRCF) (MARI: CC) in Langton, Ontario. Having established itself as a respected supplier of medical cannabis, the company is focusing on expanding all areas of operation, from cultivation to extraction, analytics and production, with a view to developing global markets. Health Canada recently granted to Maricann a new license to increase its production capacity by over 480 percent to 6,250,000 grams. The company also recently entered a collaboration agreement with a national provider of services to pharmacies to create a special medical cannabis program for physicians and patients. Maricann’s market cap is just more than USD$110 million.

In Paris, Ontario, licensed producer Emblem Corp. (OTC: EMMBF) (EMC: CC) operates a facility that consists of six controlled indoor growing rooms, with a seventh scheduled to be added by spring 2018. As part of its expansion, Emblem is completing the construction of a 30,000-square-foot facility housing a GMP extraction laboratory as well as a value-added product and pharmaceutical production facility. In October 2017, the company entered an exclusive agreement with Canntab Therapeutics to collaborate on the preclinical formulation, development, manufacturing and commercialization of a cannabinoid-based oral sustained release formulation for the treatment of chronic pain, nausea and spasticity in patients with multiple sclerosis. Emblem’s market valuation is USD$1 million (CAD$116+ million).

MedReleaf Corp. (OTC: MEDFF) (LEAF: CC) is a licensed producer, in addition to being the only ISO 9001 certified medical cannabis producer in North America. This is a quality management standard set by the International Standards Organization (ISO) and requires certified companies to adhere to strict quality control and assurance procedures. With a market cap of over USD$1.2 billion (CAD $1.5+ billion), MedReleaf has state-of-the-art marijuana growing facilities in Ontario and uses proprietary plant breeding programs and advanced cultivation methodologies. The company also conducts research and development into the therapeutic benefits of cannabis and manufactures a range of premium medical cannabis products.

By forming strategic partnerships to grow their facilities, these licensed producers are well positioned to meet increased demand for Canada’s supply-hungry marijuana market, and with more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates, and an established operations team in place, ABcann is well-positioned as market leader.

For more information on ABcann Global Corp., visit ABcann Global Corp. (OTCQB: ABCCF) (TSX.V: ABCN).

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Tuesday, November 14th, 2017 Uncategorized Comments Off on $EMMBF Canadian Licensed Producers Prepare for Recreational Cannabis Legalization
Top Small Cap Market News